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ABSTRACT 
 
The speed that bacterial pathogens gain resistance to antibiotics is alarming. Designing new 
antibacterial agents is urgent, but it requires understanding their bacterial targets at the 
molecular level to achieve high specificity and potency. In this thesis, I discuss the 
structural and biochemical investigations of three potential protein targets for antibiotics. 
The first is a UDP-Glc/GlcNAc 4-epimerase, called Gne, from the human pathogen 
Campylobacter jejuni. This enzyme is the sole source of N-acetylgalactosamine (GalNAc) 
in C. jejuni, which is a common component in three major glycoconjugates decorating the 
cell surface and is critical for pathogenesis. The second target protein is an integral 
membrane protein, called MraY, which catalyzes the transfer of phospho-N-acetylmuramyl 
(MurNAc) pentapeptide to a lipid carrier, undecaprenyl phosphate (C55-P), producing Lipid 
I in the peptidoglycan biosynthesis pathway. In the following step, a peripheral protein 
called MurG catalyzes transferring N-acetylglucosamine (GlcNAc) to Lipid I and produces 
Lipid II, which provides the first building block of the peptidoglycan layer. Peptidoglycan 
is uniquely bacterial, with MraY and MurG both being essential for cell viability; 
therefore, they are attractive targets for the development of antibacterial agents and work 
toward their structures is presented. Finally, MraY from Escherichia coli is the target for 
the lysis protein E from phage ΦX174. Efforts toward elucidating the EcMraY-E complex 
structure are demonstrated here. In total, this thesis provides important data toward a full 
mechanistic understanding of these important antibacterial targets. 
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C h a p t e  r   1 
 
 
Introduction 
 
 
Discovery of penicillin in 1928 by Dr. Alexander Fleming saved a large number of patients 
suffering from a variety of infectious diseases caused by bacterial pathogens and opened the 
world to the antibiotic age. Since then, a variety of antibiotics were discovered and used in 
clinics, but the pathogens that were targeted quickly developed resistance (CDC, 2013). For 
example, streptomycin was discovered in 1944 to treat tuberculosis, but a Mycobacterium 
tuberculosis strain that is resistant to the antibiotic appeared already during patient treatment 
(Davies & Davies, 2010). Emergence and subsequent spread of antibiotic resistance occurs 
so rapid that as a society we are running out of effective antibiotics to treat patients resulting 
in the increased prevalence of multi-drug resistant strains. 
 
 
Antibiotic resistance is considered a pandemic. At least two million people are infected with 
antibiotic-resistant species resulting in 23,000 deaths each year in the United States (Frieden, 
2013). The result of humans’ overuse and misuse of antibiotics for therapeutic and 
prophylactic purposes and the unregulated disposal to the environment, bacterial species face 
constant selection pressure and they are winning the race against antibiotic development. If 
urgent action is not taken, such as tightly regulating the use of antibiotics globally, returning 
to the pre-antibiotic era will be inevitable. Extended periods of hospitalization due to longer 
treatment of infections will be an enormous financial burden on health care systems 
worldwide and we will lose lives to infectious diseases that were once treatable. 
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What is clear is that there should be constant and increased efforts in the search for new 
antibiotic targets and new antibacterial agents with complete understanding of their modes 
of action and molecular mechanisms. During my Ph.D. training, I focused on the structural 
and biochemical investigation of promising antibiotic protein targets in human pathogens. 
The goal is that this work can lead to development of specific and potent antibacterial agents. 
I have primarily focused on the three human pathogens Campylobacter jejuni, Escherichia 
coli, and Mycobacterium tuberculosis. In these organisms, my goal was to understand 
enzymes central to bacterial glycobiology. 
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C h a p t e r  2 
 
 
The structure of the UDP-Glc/GlcNAc 4-epimerase from the human pathogen 
Campylobacter jejuni 
 
 
ABSTRACT 
 
Worldwide, the food-born pathogen Campylobacter jejuni  is the  leading bacterial 
source of human gastroenteritis. C. jejuni produces a variety of diverse cell-surface 
carbohydrates that are essential for pathogenicity. A critical component of these oligo- 
and polysaccharides is the sugar N-acetylgalactosamine (GalNAc). The sole source of 
this sugar is the epimerization of UDP-N-acetylglucosamine (GlcNAc), a reaction 
catalyzed by the enzyme UDP-GlcNAc 4-epimerase (Gne). This enzyme is unique 
among known bacterial epimerases in that it also catalyzes the equivalent reaction with 
the non-N-acetylated sugars. Understanding how CjGne catalyzes these various 
interconversions is critical to designing novel inhibitors of this enzyme. Here, to further 
the mechanistic understanding we present a 2.0Å structure of CjGne with its NAD+ co- 
factor bound. Based on novel features found in the structure we perform a variety of 
biochemical studies to probe the mechanism and compare these results to another 
structurally characterized bifunctional epimerase from humans GalE. We also show that 
ebselen, previously identified for inhibition of HsGalE, is active against CjGne, 
suggesting a route for antibiotic development. 
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INTRODUCTION 
 
Campylobacter jejuni, a microaerophilic pathogen, is a commensal of chickens and other 
avians and the most prevalent member of the Campylobacter spp., which are the leading 
causes of bacterial gastroenteritis worldwide (Kaakoush, Castaño-Rodríguez, Mitchell & 
Man, 2015; World Health Organization (WHO), 2017). It can be associated with post- 
infectious sequelae include Guillain-Barrè syndrome (Nachamkin, Allos & Ho, 1998), 
bacteremia (Fernández-Cruz et al., 2010), and reactive arthritis (Pope, Krizova, Garg, 
Thiessen-Philbrook & Ouimet, 2007). The C. jejuni glycome contains a number of surface- 
accessible carbohydrate structures required for interactions with the various hosts that 
include capsular polysaccharide (CPS), lipooligosaccharide (LOS), and N- and O-linked 
glycans (Abdi et al., 2012; Bacon et al., 2001; Day, Semchenko & Korolik, 2012; Ben N. 
Fry et al., 1998; Benjamin N. Fry et al., 2000; Guerry et al., 2002; Linton et al., 2005a). 
Variability in the nature of the surface glycans challenges the development of anti- 
Campylobacter therapies (Parkhill et al., 2000; Szymanski et al., 2003). 
 
 
All of the exposed currently identified glycans in C. jejuni contain a GalNAc residue 
(Bernatchez et al., 2005; Mahdavi et al., 2014; Szymanski et al., 2003; N. M. Young et al., 
2002), which is only produced by the epimerization of GlcNAc by the enzyme encoded by 
the gene gne (UDP-GlcNAc 4-epimerase). It was recently reannotated from galE (UDP-Gal 
4-epimerase) due to the discovery of the UDP-GlcNAc epimerization activity (Bernatchez et 
 
al., 2005) (Fig. 2.1.A). In the C. jejuni genome (strain NCTC11168), this gene is located 
between the gene clusters of the N-linked glycosylation and LOS biosynthesis pathways 
(Karlyshev, Ketley & Wren, 2005). The gene in C. jejuni was first believed to be involved 
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in the LPS biosynthesis pathway (Ben N. Fry et al., 1998), but later a functional role in N- 
linked glycosylation was also determined (Linton et al., 2005b; Szymanski, Ruijin, Ewing, 
Trust & Guerry, 1999). Furthermore, experiments with an insertional mutant of gne 
indicated that it is responsible for providing GalNAc residues to the three major cell-surface 
glycoconjugates (Bernatchez et al., 2005). The bifunctional protein CjGne represents a 
potential therapeutic target as most oligosaccharides in C. jejuni, which contain a GalNAc 
residue, are required for pathogenesis (K. T. Young, Davis & DiRita, 2007). A mechanistic 
understanding is key to developing therapeutics that target this unusual epimerase. 
 
 
UDP-hexose 4-epimerases, including CjGne, belong to a protein family of short-chain 
dehydrogenases/reductases (SDRs) (Kavanagh, Jörnvall, Persson & Oppermann, 2008). 
SDR enzymes possess diverse substrate specificity (Persson & Kallberg, 2013), as seen in 
the UDP-hexose 4-epimerases that have undergone detailed characterization (Beerens, 
Soetaert & Desmet, 2015). Structures of UDP-hexose 4-epimerases are available from all 
three domains of life: GalE from Escherichia coli (EcGalE) (Thoden, Frey & Holden, 1996, 
2002; Thoden & Holden, 1998), GalE from Trypanosoma brucei (TbGalE) (Shaw et al., 
2003), GalE from Pyrobaculum calidifontis (PcGalE) (Sakuraba, Kawai, Yoneda & 
Ohshima, 2011), GalE from Homo sapiens (HsGalE) (Thoden, Wohlers, Fridovich-Keil & 
Holden, 2000, 2001), GalE from Thermotoga maritima (TmGalE) (Shin et al., 2015), WbpP 
from Pseudomonas aeruginosa (PaWbpP) (Ishiyama, Creuzenet, Lam & Berghuis, 2004), 
and WbgU from Plesiomonas shigelloids (PsWbgU) (Bhatt et al., 2011). A classification 
scheme has been proposed for substrate preference of the UDP-hexose 4-epimerases 
(Ishiyama et al., 2004). The scheme categorizes the epimerases in three different groups 
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depending on the side chain size of six key active site residues. Group 1 epimerases, such 
as EcGalE and TbGalE, interconvert only the non-acetylated moieties, UDP-Glc and UDP- 
Gal. Group 3 enzymes prefer epimerizing acetylated moieties and the examples are PaWbpP 
and PsWbgU. Group 2 members, which include CjGne and HsGalE, catalyze 
interconversion of both the non-acetylated and acetylated UDP-hexoses. All of the UDP- 
hexose 4-epimerases structurally characterized so far are functional either in the Leloir 
pathway for galactose metabolism or the LPS O-antigen biosynthesis pathway. No epimerase 
known to act on multiple pathways has yet been a subject of structural studies. 
Toward a mechanistic understanding of this bifunctional multi-pathway enzyme, here we 
provide a 2.0Å crystal structure of NAD+-bound CjGne. Structural characteristics of CjGne 
that are common or distinct to its homologs are discussed. Based on the structural features 
and the epimerization results of the wild type and its mutants, we propose some critical 
residues of CjGne that are catalytically or structurally important for shaping its substrate- 
binding site and determining substrate specificity. 
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RESULTS 
 
The overall architecture of CjGne bound with NAD+ 
 
The gene for CjGne was cloned into an expression vector, induced in E. coli, purified by 
chromatography, and crystallized via conditions initially obtained through standard screens. 
Crystals diffracted to 2.0Å and a complete data set was collected. Data were processed using 
standard tools and the structure was solved by molecular replacement using BaGalE (PDB 
entry: 2C20). The fully refined model contained a dimer of CjGne with an R-factor of 19.5% 
and an Rfree of 22.5%. A complete atomic model containing residues 2–328 was attained for 
each with an RMSD of 0.38 Å between the two copies. Crystallographic statistics are found 
in Table 2.1. The two copies in the asymmetric unit are related by a two-fold rotational axis 
(Fig. 2.1.B). Consistent with this as a dimer interface, in solution the enzyme purified as a 
dimer as detected by SEC-MALLS (Fig. 2.1.C). For clarity, subunit A (indicated in Fig. 
2.1.B) will be used in figures when only one is present. 
 
 
The general structure of CjGne is consistent with that seen for related epimerases with a 
Glycosyltransferase A fold. Each subunit of CjGne contains two domains and one NAD+ 
cofactor (Fig. 2.1.D). The domain that contains the N-terminus (M1-Y174, I230-H260, I295- 
D312) is composed of a central, twisted, parallel, seven‐stranded, β‐sheet flanked on each 
side by four α-helices. This domain resembles a ‘Rossmann-fold’ motif where NAD+ binds 
that is commonly present in SDR enzymes (Lesk, 1995) and will be referred to as the NAD- 
binding domain (NBD). The substrate-binding domain (SBD) containing mostly C-terminal 
residues (F175-F229, G261-L294, D313-C328) is composed of three -helices and two 
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parallel -strands. Previous structural studies of related epimerases demonstrate that the 
UDP-hexose substrate resides in the cleft between the two domains with the UDP moiety 
primarily contacting SBD (Thoden, Frey, et al., 2002). 
 
 
The conserved NAD-binding domain (NBD) 
 
Both NAD+ and NADH have been previously resolved in crystal structures of related 
epimerases (Thoden et al., 1996). The only structural difference between NAD+ and NADH 
is in the nicotinamide ring (Fig. 2.2.A) and NAD+ would have the nicotinamide ring that is 
planar. At this resolution, analyzing the 2Fo-Fc map around the nicotinamide ring did not 
conclusively demonstrate whether or not the ring is planar. (Fig. 2.2.B). We instead 
compared Fo-Fc maps after refining the data with the model of NAD
+ and NADH. When 
NADH was used in refinement an additional positive density in the Fo-Fc map appeared in 
the nicotinamide ring; no density was seen for NAD+ (Fig. 2.2.B). The unaccounted-for 
electron density with NADH is consistent with the additional electrons found in the 
nicotinamide ring of NAD+, which we conclude is the major state in our crystal form. The 
nicotinamide ring adopts the syn conformation with respect to the ribose as seen in some of 
the EcGalE (PDB ID: 1NAI, 1XEL, 1LRL) and all of the HsGalE structures (PDB ID: 1EK5, 
1EK6, 1HZJ). 
 
 
The interaction with NAD+ seen here is characteristic of related NAD-binding domains. The 
details were first described in the structure of GalE from E. coli where a series of conserved 
residues line the binding pocket (PDB ID: 1NAI) (Bauer, Rayment, Frey & Holden, 1992). 
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In CjGne, Ser34, and Lys35 forms one more and one less hydrogen bond than the 
corresponding residues in EcGalE, respectively (Fig. 2.2.C). In EcGalE, an additional 
residue Lys84 stabilizes the pyrophosphate group of NAD+ via two hydrogen bonds, while 
the corresponding residue Ile82 in CjGne makes none (Fig. 2.2.C). Overall, seven residues 
(Asp31, Asn21, Ser34, Lys35, Asp56, Leu57, Asn97) are in hydrogen-bonding distance with 
the adenosine of NAD+. Two residues (Tyr11, Ile12) and four residues (Phe78, Tyr146, 
Lys150, Tyr174) are interacting through hydrogen bonds with the pyrophosphate group and 
nicotinamide/ribose of NAD+, respectively. 
 
Apo-substrate-binding pocket is expanded 
 
In a comparison to the other bifunctional epimerase HsGalE, our apo-CjGne structure aligns 
best with the only available apo-GalE ‘resting enzyme’ from human (PDB ID: 1EK5) 
(Thoden et al., 2000) with an RMSD of 1.292 Å. When the SBDs of CjGne and HsGalE are 
aligned, the RMSD value is 1.224 Å, close to the overall RMSD. In order to find differences 
in the substrate-binding sites, CjGne was aligned only with the SBD of HsGalE bound to 
UDP-GlcNAc (PDB ID: 1HZJ) (Fig. 2.3.A). A careful look at the superposition revealed 
that while R300 and D303 of HsGalE stabilize UDP-GlcNAc through some hydrogen bonds 
(Fig. 2.3.B), the corresponding residues (R287 and D290) of CjGne make no contact with 
UDP-GlcNAc (Fig. 2.3.C). Instead, D290 forms a hydrogen bond with R287, which in turn 
interacts with the backbone of Y190 and P191 (Fig. 2.3.CD). Interestingly, Y190 and P191 
are part of the shifted loop in CjGne that will be described in the next section. 
 
 
A shifted loop in the CjGne structure 
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Our crystal structure of CjGne revealed a surprising feature not found in any other 
structures of its related enzymes. In CjGne, one loop region (174- 
YFNAGACMDYTLGQRYPKATL-195) is shifted toward the NBD obstructing the 
substrate-binding pocket (Fig. 2.4.A). In the crystal, this shift is supported by the presence 
of a disulfide bond between C181 and the C-terminal residue, C328 (Fig. 2.4.A). Both of 
these cysteine residues are not found in related epimerases, except for closely related 
Campylobacter spp; yet notably they always occur as a pair (Fig. 2.4.BC). We presume 
disulfide bond formation results in stabilization of the shifted loop. CjGne localizes in the 
cytoplasm and, under typical media conditions, this would be a reducing environment 
incompatible with a disulfide bond. During purification fresh DTT was added to all buffers 
(pH 7.5) to maintain a reducing environment. However, the presence of the disulfide 
suggested this was insufficient. DTT is reported to be readily oxidized above pH 7.5 (Han & 
Han, 1994) and in the presence of metal ions like Ni2+ contaminants from Ni column (Getz, 
Xiao, Chakrabarty, Cooke & Selvin, 1999). TCEP was added as an alternative to the final 
protein solution and incubated overnight before setting up crystal trays. It was also added to 
cryo-protecting conditions when harvesting crystals. Although TCEP is known to be stable 
at both acidic and basic conditions (Han & Han, 1994) and active with some metal 
contaminants, the crystals acquired always had the disulfide bond. This suggests that the 
formation of the disulfide is favored by the protein. 
 
The internal cysteine forming the disulfide bond is important for activity 
 
We first examined the CjGne-catalyzed percent conversion of the four substrates (UDP-Glc, 
UDP-Gal, UDP-GlcNAc, and UDP-GalNAc) at equilibrium using capillary electrophoresis 
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(CE). After 24 hours, when the sample reaction started from either UDP-Glc or UDP-Gal, 
the ratio for the integral areas reached 23:75 (UDP-Glc:UDP-Gal) at equilibrium irrespective 
of the starting substrate (Fig. 2.5.AB and Table 2.2). Similarly, in the presence of either 
UDP-GlcNAc or UDP-GalNAc as a substrate, the reactions reached a similar ratio of 28:71 
(UDP-GlcNAc:UDP-GalNAc) at equilibrium (Fig. 2.5.AB and Table 2.2). With this assay, 
we confirmed the bifunctional activity of CjGne in interconverting similar amounts of non- 
acetylated and acetylated substrates. 
 
 
The unexpected disulfide bond brings into question whether there may be biological 
importance to these residues. To examine the roles of C181 and C328, we expressed and 
purified various cysteine mutants (C181A, C181S, C328S, ΔC328, and C181S/ ΔC328) and 
analyzed their percent conversion after 24 hours (Fig. 2.5.C and Table 2.2). All of the C181 
mutants (C181A, C181S, and C181S/ΔC328) resulted in significant loss of activity, less than 
20% of wild type conversion, irrespective of the starting UDP-hexose. For the C-terminal 
cysteine, the C328S mutant lost more than 50% of the wild-type conversion. Yet surprisingly, 
the deletion of C-terminal C328 retained the full activity of the wild type regardless of the 
substrate added. 
 
 
The similar HsGalE cysteine is not required for activity 
 
In the multiple sequence alignment of CjGne and its homologs (Fig. 2.4.E), there is no 
epimerase that has a cysteine residue at the corresponding position to C181 of CjGne. 
Instead, the human epimerase among the homologs is the only example that has a cysteine 
residue (C196) within the corresponding loop region (Hs Y185-N207) to the previously 
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mentioned loop (Cj Y174-L195) in CjGne. We expressed and purified the C196A and 
C196S mutants of HsGalE and investigated their epimerization activity at equilibrium in the 
reaction with each of the sugar substrates. Again, we confirmed the bifunctional nature of 
the enzyme. In this case, both mutants had no significant loss in activity relative to the wild 
type (Fig. 2.5.C and Table 2.2). 
 
 
The CjGne internal cysteine affects the thermal stability of the enzyme 
 
Thermal denaturation of the wild-type CjGne and its cysteine mutants was monitored 
through melting curves and calculated melting temperature (Tm) (Fig. 2.5.D and Table 2.3). 
The Tm values across the four UDP-hexose substrates within an enzyme stayed the same or 
had a difference less than 2°C. All the cysteine mutants of CjGne had the Tm values that are 
lower than the wild type by 2°C or more. The single and double mutants containing C181A 
decreased the Tm values the most by 8°C. Protein unfolding was also monitored for the 
HsGalE C196 mutants (Fig. 2.5.D and Table 2.3). Unlike those of the CjGne mutants, the 
Tm values were retained regardless of the substrates. 
 
 
Critical residues of CjGne for substrate binding and specificity 
 
We performed a structural alignment between CjGne and HsGalE bound with UDP-GlcNAc 
(PDB ID: 1HZJ) (Fig. 2.6.A). From the alignment, we identified five residues of CjGne that 
likely make polar contacts with the UDP-GlcNAc (T122, N176, P185, K192, and T194). 
Among them, both T122, either a serine or threonine, and N176 are conserved among the 
homologous sequences (Fig. 2.4.E). In order to examine their functional roles within the 
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predicted active site, we introduced mutations that retain the size, but lose polarity of the 
side chain: T122V and N176L (Fig. 2.6.A). 
 
 
Based on the classification scheme for UDP-hexose 4-epimerases (Ishiyama et al., 2004), the 
T122 and N176 residues are two of the six key residues in CjGne, determining substrate 
specificity. Another key residue, L294, was also subject to mutation varying the size of 
hydrophobic side chains (valine, methionine, and tyrosine) to investigate its role in substrate 
specificity (Fig. 2.6.A). The corresponding residue of L294 in EcGalE (Y299) was the first 
example that showed a single-residue mutation at this position to cysteine altered substrate 
specificity (Thoden, Henderson, Fridovich-Keil & Holden, 2002). 
 
 
The equilibrium assay was performed with each of the mutants. For T122V and N176L, there 
was nearly a complete loss of conversion for all of the four UDP-sugar substrates (Fig. 
2.6.B). This supports that T122 and N176 have catalytic roles that are essential for the 
epimerization activity of CjGne. T122 of CjGne is structurally aligned to S124 (EcGalE), 
which is suggested to mediate catalysis by being hydrogen-bonded to Y149 (EcGalE), an 
active site base, and to the 4’-hydroxyl group of the glucosyl ring of UDP-Glc (Yijeng Liu 
et al., 1997). Also, in HsGalE, the corresponding residue, S132 interacts with the 4’-OH 
group of the hexose (Fig. 2.6.A). In CjGne, T122 and Y146 (Y149 in EcGalE) are not in 
hydrogen-bonding distance. 
 
 
N179 of EcGalE (N176 in CjGne) has been suggested as one of the amino acid residues that 
contact the hexose portion of UDP-Glc/Gal within a hydrogen-bonding distance and thereby 
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important for binding of the substrate in the E. coli (Thoden et al., 1996). Similarly, N176 
(CjGalE) forms a hydrogen bond with 6’-hydroxyl group of UDP-GlcNAc bound to HsGalE, 
but through the amino group. Alternatively, the amino group of N187 (HsGalE) interacts 
directly with the two phosphoryl oxygen atoms of the β-phosphate group of the nucleotide 
(Fig. 2.6.A). With substrate bound, N176 may re-orient in CjGne to make this same 
interaction. 
 
 
The epimerization assay was also performed for the L294V, L294M, and L294Y mutants to 
investigate if the size of the L294 side chain alters substrate specificity of CjGne (Fig. 2.6.B). 
None of the mutants retained activities at a comparable level to those of the wild type with 
all four substrates. However, interconversion of non-acetylated substrates was least disrupted 
with L294V among the mutants, whereas L294M was most favorable for activity than the 
other two mutants with acetylated substrates. 
 
 
Ebselen inhibiting HsGalE is a potential inhibitor of CjGne 
 
Few studies have reported inhibitors of GalE, and none of them are promising for further 
drug development. One literature reported ebselen, an organoselenium compound, inhibits 
HsGalE with nanomolar IC50 (0.014 M) (Urbaniak et al., 2006). Since CjGne possesses a 
bifunctional activity just like HsGalE, we predicted that the inhibitors that are potent to 
HsGalE would also exert inhibitory effect on CjGne. An inhibition assay of CjGne using 
capillary electrophoresis was performed in the presence of ebselen (Fig. 2.7). Indeed, the 
inhibition was almost complete when ebselen was incubated with the enzyme and either 
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UDP-Gal or UDP-GalNAc, while the results were slightly less dramatic in the reactions 
with either UDP-Glc or UDP-GlcNAc (13% and 22% of the wild-type activity was retained, 
respectively). 
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DISCUSSION 
 
In this study, we provide the first structural and biochemical characterization of CjGne, the 
bifunctional UDP-Glc/GlcNAc 4-epimerase which catalyzes the production of GalNAc, a 
critical component of the major surface polysaccharides in C. jejuni. This functionally 
separates Gne from other UDP-Glc/GlcNAc 4-epimerases that either work in the Leloir 
pathway for galactose metabolism or are part of the LPS biosynthesis pathway. 
 
 
A surprising result is the presence of a structural disulfide bond in CjGne. Expressed 
heterologously in the E. coli system, one expects cysteines to be reduced in the cytosol 
(Hatahet, Boyd & Beckwith, 2014). Other exceptions have been reported where structural 
disulfides in cytosolic proteins of thermophilic archaeal species protect them from 
denaturation at high temperature (Jorda & Yeates, 2011). C. jejuni is a moderate thermophilic 
species thriving at 37–42°C (Hofreuter, 2014) with a Tm for CjGne at 57°C (Fig. 2.5.D 
and Table 2.3). The presence of a structural disulfide bond might help CjGne tolerate 
growing at high temperature. 
 
 
The cysteine at position 181 is not conserved (Fig. 2.4.E), yet replacing C181 with either 
alanine or serine led to a loss of activity. In the structure, a water mediated network connects 
the phosphate groups of the substrate to the backbone of the C181 residue. These are unlikely 
to be disrupted by the simple mutations. When the other half of the disulfide pair, C328, was 
replaced with a serine, less than 50% wild-type conversion was retained. Surprisingly, 
deletion of the C-terminal cysteine (C328) was fully active. In total, we can conclude that the 
disulfide bond is not required for catalysis. However, the cysteines are important for full 
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activity. Cysteines often make hydrophobic contacts and the effects from the loss of the 
spatial hydrophobic environment may provide rationale for the reduction in activity upon 
mutation to serine. Supporting this, all the cysteine mutants of CjGne reduced the overall 
stability of the protein (Fig. 2.5.D and Table 2.3). This suggests general structural roles that 
could affect catalysis. 
 
 
A major feature of our CjGne structure is the shifted loop region (Y174-L195) toward the 
active site. The presence of the disulfide suggests that this may fix the conformation of the 
loop. The sequence of this region is conserved across other Campylobacter species and the 
electron density shows the conformation is well ordered. In this conformation, the protein 
would be expected to be inhibited, perhaps a response to the complicated environments 
experienced by C. jejuni. 
 
 
While the cysteines play a functional role in C. jejuni, a related cysteine in the functional 
homolog HsGalE was not required for full activity. In the structure of the human, there is no 
shift of the corresponding CjGne loop (Y174-L195). This lends credence to the importance 
of these residues in the C. jejuni enzyme. 
 
 
The mechanism of this class of epimerases has been elucidated over time; however, there 
remain some details to be resolved. We chose candidate residues that are predicted to be 
critical in substrate binding or specificity from the structural and sequence alignments with 
the human epimerase in complex with NADH and UDP-GlcNAc (PDB entry: 1HZJ). Both 
of the T122V and N176L mutants killed almost all of the activity irrespective of the substrate 
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tested. This result is indicative of catalytic importance of the residues. The highly 
conserved serine residues of the other homologs aligned with T122 of CjGne have been 
shown to play a role in mediating the electron transfer during the catalytic mechanism. The 
asparagine residue corresponding to N176 in CjGne is also highly conserved across species. 
The N195 residue in the PsWbgU (N176; CjGne), for example, forms two hydrogen bonds 
via the carbonyl oxygen and the amine group with the NH-group and the oxy bridge of the 
diphospho moiety of UDP-GlcNAc, respectively. Based on the high conservation and 
previous functional characterization in other homologs, T122 and N176 of CjGne are likely 
to require polar side chains to be either directly or indirectly involved in catalysis and to 
interact with the substrate bound, respectively. 
 
 
Along with T122V and N176L, L294 of CjGne was subjected for mutagenesis studies 
because there were cases where mutation of the single residue in the same position in its 
homologs altered substrate specificity. Previous studies demonstrated that Y299C of EcGalE 
(Thoden, Henderson, Fridovich-keil & Holden, 2002) allowed, but C307Y of HsGalE 
(Schulz et al., 2004) and S306Y of EcGalEO86:B7 (Guo, Li & Wang, 2006) lost the conversion 
activity of acetylated substrates, respectively. In contrast, mutation of the corresponding 
residue (S317) from PaWbpP to tyrosine resulted in complete loss of activity, so no further 
insights regarding side chain size of this residue for substrate specificity was available 
(Ishiyama et al., 2004). We mutated the residue in the same position, L294, of CjGne into 
valine, methionine, and tyrosine to see if various sizes of hydrophobic side chains can affect 
the activities of any UDP-hexose substrate. We predicted L294M retains bifunctionality of 
CjGne, whereas L294V and L294Y preferentially convert acetylated and non-acetylated 
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sugar substrates, respectively. None of the three mutants of L294 retained the full activity 
of the wild type, but showed similar levels of reduction between UDP-Glc and UDP-Gal and 
generally more reduction with UDP-GalNAc. Approximately 50% reduction in L294V 
activity with non-acetylated substrates can be explained by the smaller hydrophobic side 
chain of valine increases the active site volume, rendering the binding to non-acetylated 
and/or acetylated substrates less specific. Also, the hydrophobic interaction between leucine 
and the methyl group of the N-acetylated moiety on C2 on UDP-GlcNAc from the human 
enzyme seems to be disrupted in CjGne by the replacement with valine, thereby resulting in 
a larger reduction in conversion activity of the acetylated substrates. Methionine is in similar 
size as leucine in L294M mutant and activities for both non-acetylated and acetylated 
substrates were all at similar levels except for UDP-GlcNAc, but the epimerization is much 
less efficient than that catalyzed by the wild type, which is probably because of different 
chemical properties of sulfur replaced from carbon and/or the different position of a methyl 
group. In L294Y mutant, the bulky side chain of tyrosine seemed to reduce the active site 
volume, thus leading to the highest loss of epimerization with UDP-GalNAc. Taken together, 
we demonstrate the variants of the active site residue (L294) can alter substrate specificity, 
although the previously predicted pattern did not fit here. 
 
 
Lastly, the inhibition of CjGne by ebselen provides evidence for this as a small molecule 
target, but ebselen itself is not a likely route as it has been reported to target myriads of 
biological pathways (Azad & Tomar, 2014). It will be important to find inhibitors that are 
specific to CjGne. The search for such inhibitors is ongoing. 
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In conclusion, based on a high-resolution CjGne/NAD+ crystal structure and biochemical 
data from mutants, we proposed some critical residues of CjGne that are catalytically or 
structurally important. These findings along with its observed susceptibility to a HsGalE 
inhibitor, suggest a route for antibiotic development. 
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Figure 2.1. The 2.0Å crystal structure of CjGne in complex with NAD+. A, A catalytic reaction scheme of CjGne 
involving four substrates, UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, and 4-ketose intermediate. B, (Top) An 
asymmetric unit contains two molecules of CjGne with a two-fold symmetry. (Bottom) The two molecules are rotated 
by 90°. In both cases, a monomer in the cartoon representation is colored with rainbow; N-terminus is with red and C- 
terminus is with blue. One NAD+ molecule in each monomer is shown in stick representation with the purple backbone. 
C, The SEC-MALL result shows CjGne forms a dimer (~72 kDa; blue) in solution as compared to the bovine serum 
albumin (BSA) standard (monomer: ~60 kDa; dimer: ~128 kDa; red). D, A monomer is colored the same as in A. 
Additionally, the disulfide bond is depicted in yellow spheres. NBD and SBD are also labeled. 
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Figure 2.2. NAD+ and NBD. A, Comparison of the chemical structures of NAD+ and NADH. The only difference lies 
in the nicotinamide ring, depicted as a R group. B, On the left, the 2Fo-Fc map that is refined with NAD+ is shown in 
mesh at 2  and the magnified view of the nicotinamide ring. On the right, the Fo-Fc map that is refined with NADH is 
shown in mesh at 3 . C, On the left, a monomer of CjGne in the same orientation as in Fig. 1D is colored gray. NAD+ 
is shown in stick representation and its backbone is purple. Ile82 is indicated by a red arrow. On the right, this is a 
magnified view of the NBD. The residues that are in a hydrogen-bonding distance to adenosine, phosphates, and 
nicotinamide/ribose are shown in stick representation and colored orange, blue, and green, respectively. The residues 
that interact with NAD+ via backbone are bolded. Hydrogen bonds are shown in black dashed lines. 
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Figure 2.3. Substrate-binding domain (SBD) of CjGne. A CjGne monomer is shown in complex with NAD+ and UDP- 
GlcNAc from HsGalE (PDB ID: 1HZJ). A, Aligned CjGne (slate) and the HsGalE SBD (green cyan) in the box region. 
Y190, P191, R287, and D290 of CjGne and R300 and D303 of HsGalE are shown in stick representation. B, Same region as 
A, but only HsGalE is shown along with the polar contacts in black dashed lines. C, Same region as A, but CjGne and UDP-
GlcNAc from HsGalE are shown with polar contacts in black dashed lines. D, Same region as A, but only CjGne is shown 
with polar contacts between R287/D290 and Y190/P191. 
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Figure 2.4. Unique features of CjGne. A, Structural alignment between CjGne/NAD+ (slate) and HsGalE/NADH/UDP- 
GlcNAc (PDB ID: 1HZJ) (green cyan). The SBD is magnified in the box. NAD+, NADH, and UDP-GlcNAc are shown 
in the stick representation. C181 and C328 of CjGne along with the disulfide bond and C196 of HsGalE are also in the 
stick representation. B, The full length of CjGne. C, Multiple sequence alignment of Campylobacterales was performed 
in ClustalX 2.1. Only two alignment regions (Y174-L195 and D312-C328; CjGne numbering) that are highlighted in the 
sequence scheme on the top are shown. The background coloring is as follows: aromatic (cyan), hydrophobic (blue), 
polar (green), glycines (orange), negative charge (purple), positive charge (red), prolines (yellow), and unconserved 
(white). D, A phylogenetic tree of the Campylobacterales was drawn in NJplot. E, Multiple sequence alignment of CjGne 
and its homologs. The alignment with only the region from Y174 to L195 (CjGne numbering) is shown here. The 
sequences that are used here are, from the top, Gne from Campylobacter jejuni, GalE from Homo sapiens, GalE from 
Escherichia coli, GalE from Trypanosoma brucei, WbpP from Pseudomonas aeruginosa, GalE from Thermotoga 
maritima, and GalE from Pyrobaculum calidifontis. The color scheme is the same as in C. F, A phylogenetic tree of the 
CjGne homologs was drawn in NJplot. 
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Figure 2.5. Epimerization assays of the wild-type and cysteine mutants of CjGne and HsGalE. A, An example of 
the % conversion of UDP-Glc to UDP-Gal by CjGne measured in capillary electrophoresis. The equation used to 
calculate % conversion is provided in the box. B, The results of % conversion of each of four substrates by CjGne. Each 
reaction was repeated for three times and the error bars indicate the standard deviations. C, Normalized % conversion of 
UDP-GlcNAc by the wild type and cysteine mutants of CjGne (slate) and HsGalE (green cyan). Each reaction was 
repeated for three times and the error bars are based on the calculation provided in Materials and Methods. D, The melting 
temperature values (Tm) of the wild type and cysteine mutants of CjGne (slate) and HsGalE (green cyan) in the 
presence of UDP-Glc. Each measurement was repeated for three times and the error bars indicate the standard 
deviations. 
29 
 
 
 
Figure 2.6. Predicted active site of the CjGne/NAD+ complex. A, On the left, structural alignment between 
CjGne/NAD+ and UDP-GlcNAc from the HsGalE/NADH/UDP-GlcNAc (PDB ID: 1HZJ). In the center, the putative 
active site of CjGne is magnified with T122, N176, and L294 labeled. On the right, the catalytic site of HsGalE is 
magnified to the same extent as that with CjGne with S132, N187, and C307 labeled. Hydrogen bonds are indicated as 
black dashes. B, Normalized % conversion of UDP-Glc, UDP-Gal, UDP-GlcNAc, and UDP-GalNAc by the wild type 
and catalytic mutants of CjGne. Each reaction was repeated for five times except for N176L only for once. The error bars 
are based on the calculation provided in Materials and Methods. 
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Figure 2.7. Inhibition of CjGne by ebselen. Chemical structure of ebselen is shown in the top right corner. Each 
inhibition reaction was repeated for three times except for the one with UDP-GalNAc. The error bars are calculated based 
on the equation provided in Materials and Methods. 
31 
 
 
 
 
Table 2.1. Statistics of X-ray data collection and refinement. Values in parentheses are from the highest resolution 
shell. RMS, root mean square. 
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Table 2.2. Average percent conversion values and their standard deviations of the substrates by CjGne and 
HsGalE. The protein samples include the wild type and mutants. Ebselen, an inhibitor, was added only to CjGne. The 
normalized average percent conversion values and standard deviations of UDP-hexose substrates are written 
(Calculations are reported in Materials and Methods). The #, §, and *marks refer to a single, duplicate, and quintuplicate 
measurement, respectively. The rest of the values are from triplicates. 
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Table 2.3. Average melting temperatures (°C) and their standard deviations of the wild-type and mutants of CjGne 
and HsGalE. A * mark refers to a single measurement. The rest of the values are from at least duplicates. Standard 
deviations with zero are not written. 
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MATERIALS AND METHODS 
 
Materials and chemicals 
 
Genomic DNA of C. jejuni NCTC11168 (#700819D-5) was purchased from ATCC 
(Manassas, VA). Two constructs of HsGalE with either N-terminal (pET28a vector) or C- 
terminal (pET31B vector) hexahistidine (His6) tags were kindly provided by the Holden 
Group at the University of Wisconsin, Madison. The former was used for capillary 
electrophoresis and the latter was used for stability assays, each described below. E. coli 
NiCo21(DE3) competent cells were obtained from New England Biolabs Inc. (Ipswich, 
MA). UDP-Glucose, UDP-Galactose, UDP-GlcNAc, UDP-GalNAc, NAD+), dithiothreitol 
(DTT), tris (2-carboxyethyl) phosphine (TCEP), and bovine serum albumin (BSA) were 
from Sigma-Aldrich (St. Louis, MO). Ebselen (2-phenyl- 1,2-benzisoselenazol-3(2H)-one) 
was from Cayman Chemical (Ann Arbor, MI). 
 
 
Cloning of gne 
 
The plasmid encoding gne (cj1131c) of C. jejuni was constructed by one-step enzymatic 
DNA assembly through Gibson cloning (Gibson et al., 2009). Briefly, the gne gene and the 
plasmid for insertion were amplified from genomic DNA of C. jejuni NCTC11168 and a 
pET33b-derived vector, respectively, using primers with ca. 40 bp of homology to each 
other. 5 L of DNA sample (0.7 L of the amplified gne gene (10 ng/L) plus 4.3 L of the 
amplified vector (10 ng/L )) was added to 15 L of a master mix solution including T5 
exonuclease, Phusion DNA polymerase, and Taq DNA ligase, then incubated at 50°C for 
60 min. To avoid self-colonies from the template-vector, the PCR product amplified from 
the 
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vector was treated with DpnI. The final construct contained a N-terminal his6-tag followed 
by a thrombin cleavage site (N-MGGSHHHHHHGLVPRGS-gne-C). All DNA constructs 
were confirmed by sequencing. 
 
 
Generation of point mutations 
 
All mutations, including T122V, N176L, L294V, L294M, L294Y, C181A, C181S, C328S, 
 
ΔC328, C181S-ΔC328, C196A (HsGalE), and C196S (HsGalE) were prepared in a mixture 
solution containing Phusion® High-Fidelity PCR Master Mix with HF Buffer from New 
England Biolabs Inc. (Ipswich, MA), the DNA template of the QK45AA mutant (based on 
the surface entropy reduction prediction (Cooper et al., 2007)), and primers with or without 
5% DMSO (Chester & Marshak, 1993). The recommended PCR protocol for using the 
Phusion® HF PCR MM from NEB Inc. was used. 
 
Expression and purification of CjGne 
 
Constructs were transformed and expressed in E. coli NiCo21(DE3) strain that are originally 
derived from BL21(DE3). Cells were grown in cultures of 2xYT with kanamycin (35 g/mL) 
to an optical density of OD600 0.5–0.7, then induced with 0.4 mM isopropyl -D- 
thiogalactoside (IPTG, Anatrace, Maumee, OH) at 37°C for 6 h. Cells were harvested by 
centrifugation (4000 rpm, 20 min, 4C), resuspended in lysis buffer (20 mM Tris-HCl, pH 
7.5, 100 mM NaCl, 1 mM DTT), and lysed by three passes through a microfluidizer (18 
kpsi), and centrifuged at 12,000 rpm for 20 min at 4C. Proteins were purified from the 
supernatant by nickel-affinity chromatography followed by size-exclusion chromatography. 
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Briefly, the cell lysate was modified to 10 mM imidazole then passed through a 1 mL pre- 
equilibrated Ni-NTA agarose resin (Qiagen, Germantown, MD), washed with 30x column 
volumes of 20 mM imidazole-containing buffer, then eluted with 20 mL of 250 mM 
imidazole-containing buffer. The elution was concentrated using a 10-kD cut-off Amicon® 
Ultra-4 Centrifugal Filter (Millipore) and further purified by either a Superdex-200 16/60 or 
Superdex-200 10/300 gel-chromatography column (GE Healthcare, Little Chalfont, UK). 
The fractionated protein was concentrated again using the Amicon® Centrifugal Filter, flash 
frozen, and stored at -80°C. 
 
 
Size-exclusion chromatography and multi-angle light scattering (SEC-MALS) 
 
Purified protein was analyzed by SEC-MALLS (Wyatt Technology, Santa Barbara, CA). 
Briefly, a Shodex KW-804 column (Showa Denko America, Inc., New York, NY) was 
equilibrated in running buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 10% glycerol, 10 
mM ME). 100 g of either BSA as a standard or CjGne were injected and run at 0.5 mL/min 
for 30 min. Data analysis was performed using Astro 5.3.4 software. For the sample run, 
peaks from LS, dRI, and UV (280 nm) detectors were aligned by defining baseline and 
applying band broadening values from the BSA run. 
 
 
Crystallization of CjGne and X-ray diffraction 
 
For crystallization, the purified QK45AA optimized variant of CjGne was pre-incubated with 
5 mM UDP-GlcNAc at 4°C overnight. Crystallization screening was performed by sitting-
drop vapor-diffusion with commercially available screens (Hampton Research, Qiagen, 
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Emerald BioSystems) and then incubated at room temperature.  Initial  conditions were 
refined by additive screening using the Additive ScreenTM (Hampton Research). The final 
drop consisted of 0.2 L of mother liquor (1.3 M sodium acetate trihydrate (pH 7.0) with 
50 mM sodium malonate) and 0.2 L of protein (16–20 mg/mL). Crystals grew to full- size 
after several days. For cryo-protection, crystals were transferred to a drop containing 70% 
reservoir solution and 30% glycerol for 5 sec then flash frozen in liquid nitrogen. 
Diffraction data were collected from a single crystal at beamline 12–2 at the Stanford 
Synchrotron Radiation Lightsource (SSRL). 
 
 
Structural determination and refinement 
 
Images were collected on a Dectris Pilatus 6M pixel detector. Diffraction data were 
integrated with XDS (Kabsch, 2010) and scaled with SCALA in CCP4 (Winn et al., 2011). 
Crystals were in the space group P41212 with unit cell dimensions a=b=87.7 c=261.66 and 
a complete dataset was collected to 2.0 Å. The asymmetric unit contained two copies of 
CjGne (residues 2–328), two NAD+, two acetate, seven glycerol, and 167 water molecules. 
Phases were obtained by molecular replacement using the structure of UDP-Glc 4-epimerase 
from Bacillus Anthracis as a search model (PDB entry: 2C20; 42% identity) in Phaser as 
implemented in Phenix (Adams, Afonine, et al., 2010; McCoy, 2006). Manual model 
building was performed using Coot (Emsley, Lohkamp, Scott & Cowtan, 2010). CjGne was 
refined in Phenix with final R-factor of 19.5% (Rfree = 22.5%). Statistics for data collection 
and structure determination are found in Table 2.1. 
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Epimerization assay using capillary electrophoresis 
 
Enzyme reactions were performed in 100 μL of reaction mixture containing 50 mM Tris- 
HCl (pH 8.0), 1 mM of UDP-sugar, 1 mM of NAD+, and 50 ng of CjGne at 37°C. The 
reaction was stopped after 24 hours by boiling for 5 min and then centrifuged (12,000 rpm, 
20 min) to remove protein aggregates. In the case of the inhibition assay with ebselen, 
enzyme reactions were prepared in 20 μL containing 50 mM Tris-HCl (pH 8.0), a 1 mM of 
UDP-sugar, 1 mM of NAD+, 50 ng of CjGne, and 100 M ebselen at 37°C for 24 hours. The 
reactions were then stopped by boiling for 5 min and centrifuged. The samples were 
monitored by HP 3DCE capillary electrophoresis instrument equipped with a UV-VIS DAD 
(Agilent Technologies, Santa Clara, CA, USA). The 50 cm-long capillary was packed with 
fused silica and the running buffer was 20 mM sodium tetraborate decahydrate, pH 9 (J.T. 
Baker®, Avantor Performance Materials, Center Valley, PA). The capillary was 
preconditioned for each run by washing with the running buffer for 2 min. Each sample was 
injected by pressure of 50 mbar for 10 sec and the separation was performed at 30 kV and 
detected at 260 nm (330 nm as background). The average retention times for UDP-Glc, UDP- 
Gal, UDP-GlcNAc, and UDP-GalNAc were 8.7 min, 8.9 min, 8.3 min, and 8.5 min, 
respectively. The peak area was estimated (Fig. 2.5.A) and integrated using 3D-CE 
Chemstation Rev. A.09.03. 
A fluorescence-based thermal shift assay 
 
The thermal shift assay was based on Niesen et al. (Niesen, Berglund & Vedadi, 2007). A 
real-time PCR device (CFX96 from Bio-Rad, Hercules, CA) was used to monitor protein 
unfolding through fluorescence by SYPRO Orange (Sigma-Aldrich, St. Louis, MO) at 2x 
39 
 
concentration (1:2500 dilution of 5000x stock). Fluorescence was measured using the 
FRET configuration. This configuration excites and detects in all six channels that the 
instrument has. This setting is used because no single channel contains that appropriate 
excitation and emission filter. Protein samples (2 μM) in 20 mM Tris buffer (pH 7.5) 
containing 100 mM NaCl, 1 mM NAD+, 1mM DTT, 1mM of a UDP-sugar substrate in a 
reaction volume of 50 μL were mixed in 96-well PCR plates (Bio-Rad, Hercules, CA). The 
plates were briefly spun down at 1000 rpm and placed in the device. Melting curves were 
measured starting with a 15-minute pre-chilling at 15°C then increased in 0.5°C steps to 95°C 
with 30 second incubation. The fluorescence intensity at the end of each step is plotted as a 
function of temperature. The resulting sigmoidal curve was best fit to a two-state transition. 
The inflection point of the melting curve, melting temperature (Tm), was calculated using the 
internal PCR software. 
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C h a p t e r 3 
 
 
Toward structural and mechanistic understanding of key membrane-bound 
enzymes, MraY and MurG, in the peptidoglycan biosynthesis pathway 
 
 
ABSTRACT 
 
Antimicrobial resistance from bacterial infections has become one of the biggest threats 
to human health. One popular biological pathway to target for development of 
antibacterial agents has been peptidoglycan (PG) biogenesis. Because the PG layer is 
uniquely present in bacteria and disruption of its biosynthesis causes cell lysis, designing 
inhibitor compounds that are specific to an enzyme in the pathway has been a promising 
route. The focus of this study has been on an integral membrane protein, MraY, and a 
peripheral protein, MurG, which together synthesize the lipid-linked PG building blocks 
at the cytoplasmic side of the membrane. The goal here is to obtain three-dimensional 
molecular pictures of MraY and MurG in the presence of their substrate(s) or inhibitors. 
More specifically, how the two proteins were purified and used in structural studies using 
X-ray crystallography will be discussed. The availability of structural details of these 
enzymes will provide mechanistic insights, as well as contribute to designing and 
development of selective and potent antimicrobial drugs. 
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INTRODUCTION 
 
The rapidly growing number of antibiotic-resistant and multidrug-resistant bacterial 
pathogens pose a great threat to human health (Brown & Wright, 2016; WHO, 2017). A 
large number of attractive protein targets for antibiotics have been identified from 
bacterial pathogens. However, their structural and mechanistic details are often missing, 
slowing design of antibacterial agents that are selective and potent toward each target. 
Thus, the main goal of this study will be elucidating the catalytic mechanism of selected 
protein targets by providing its structural details to help the development of novel 
antibiotics. 
 
 
Most bacteria possess the peptidoglycan (PG) layer as a major constituent of their cell 
wall, which protects the cells from the internal turgor pressure and helps them to maintain 
their cell shape (Lovering, Safadi & Strynadka, 2012). In addition, a functional 
peptidoglycan layer is required for effective cell division (Vollmer, Blanot & De Pedro, 
2008). Gram-positive bacteria have a thick peptidoglycan layer outside their single cell 
membrane, whereas Gram-negative bacteria have a relatively thinner one in the 
periplasmic space between the two membranes (Silhavy, Kahne & Walker, 2010). Even 
the Mycobacteriaceae, which has its own unique cell envelope architecture, possess the 
peptidoglycan layer and its presence is critical in their cell viability (Jankute, Cox, 
Harrison & Besra, 2015). Because the peptidoglycan layer is unique to bacteria and there 
is no peptidoglycan in human, many enzymes involved in this pathway have been the site 
of action of antibacterial agents, including the clinically important β-lactam antibiotics 
(e.g., penicillin) (Bugg, 1999). 
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The peptidoglycan biosynthesis pathway (Fig. 3.1) starts with UDP-N- 
acetylglucosamine (UDP-GlcNAc) in the cytoplasm, converting into uridine diphosphate- 
N-acetylmuramyl-pentapeptide (UDP-MurNAc-pentapeptide) by a series of enzymes 
MurA-F (Barreteau et al., 2008). UDP-MurNAc-pentapeptide then is the donor for the 
transfer of phospho-MurNAc-pentapeptide to a lipid carrier, undecaprenyl phosphate 
(C55-P), to form undecaprenyl pyrophosphoryl MurNAc-pentapeptide or Lipid I at the 
cytoplasmic side of the membrane. This reaction is catalyzed by the key integral 
membrane protein, MraY (phosphor-MurNAc-pentapeptide translocase). Another 
glycosyltransferase, MurG, attaches a GlcNAc residue to Lipid I, producing Lipid II, 
which is the building block of the peptidoglycan layer (Bouhss, Trunkfield, Bugg & 
Mengin-Lecreulx, 2008; van Heijenoort, 2007). Subsequently, Lipid II flips across the 
membrane to the other side by an integral membrane protein, flippase (MurJ), and 
undergoes polymerization forming an alternating MurNAc and GlcNAc chain and 
cross-linking between pentapeptides (typically 3–4 peptide crosslink) to complete the 
peptidoglycan layer (Matteï, Neves & Dessen, 2010; Sauvage, Kerff, Terrak, Ayala & 
Charlier, 2008). Over time, a myriad of natural product inhibitors targeting this pathway 
have been identified and used in clinics, but development of antibacterial resistance 
toward them is problematic (Silver, 2013). 
 
 
All of the enzymes in the peptidoglycan biosynthesis pathway have been structurally 
characterized in one species or another. However, mechanistic understanding of some of 
them lags behind largely due to the absence of substrate-bound structures. This is 
especially true for the enzymes in the pathway that have hydrophobic substrates (e.g., 
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MraY, MurG, MurJ). It has been a challenge to determine their high-resolution 
structures with the lipid substrate bound. In addition, selective inhibition of specific 
pathogens requires species-specific structural and functional characterization of these 
enzymes. For example, in order to treat human tuberculosis, you would want to have an 
antibiotic that targets enzymes only in Mycobacterium tuberculosis rather than those 
from all bacterial species residing in human body, some of which are beneficial to human 
health. 
 
 
Here, I will present the purification of MraY from the thermophiles Hydrogenivirga sp. 
(Hy) and Mycobacterium thermoresistibile (Mth) and the efforts toward determining a 
structure of the MraY protein bound to a substrate or novel inhibitors. Also, MurG from 
Hydrogenivirga sp. has been successfully purified and a subject of structural 
characterization using X-ray crystallography technique. 
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RESULTS 
 
MraY from Hydrogenivirga sp. (HyMraY) was prepared in high purity and yield. 
 
MraY belongs to the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase 
(PNPT) superfamily that includes other members like WecA. The first structure 
determined in this superfamily was a crystal structure of an apo form of MraY from the 
thermophile, Aquifex aeolicus (Chung et al., 2013). At the same time, our lab was also 
actively purifying and crystallizing MraY from Hydrogenivirga sp., selected from an 
expression test of MraY from many species (data not shown here). The initial purification 
protocol of the His6-MraY construct was handed over to me and I modified some of the 
steps (Fig. 3.2). I ended up acquiring protein that is purer and more homogeneous (Fig. 
3.2.C) than before by introducing 20 mM imidazole wash steps in a nickel-affinity 
column, concentrating before dialysis of the sample for a cation-exchange column, and 
extending the first gradient step in the ion exchange column protocol to better separate 
contaminants. The yield of HyMraY from 24-L culture varies in each batch, but 
approximately 2 mg is obtained on average. This amount of protein is enough to set up 
crystallization trays. 
 
Purification of HyMraY without a His-tag. 
 
Literature suggests a His-tag on either N- or C-terminus of a protein can perturb folding, 
solubility, crystal packing, and native conformation of the protein. However, there are 52 
separate pairs of protein structures in the PDB where the protein structure was solved 
with or without the His-tag and analysis suggests no statistically significant differences 
(Carson, Johnson, McDonald, Brouillette & DeLucas, 2007). In order to test if the His- 
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tag affected crystallization, a His6–3C-GS5 -HyMraY construct was generated that 
contained a protease site and a linker between the His-tag and the start of the protein. 
This was expressed, treated with an HRV 3C protease, and purified (Fig. 3.3 & 3.4). 
After complete digestion with the protease in 2–3 days, the sample was run through 
either an anion (Uno Q6) (Fig. 3.3) or cation (Uno S6) (Fig. 3.4) exchange column, each 
followed by a gel-filtration column. Most of the cleaved protein from both columns were 
pulled out of the purification columns with other contaminants. The purest protein 
without a 
His-tag was obtained from a small peak that came off from the anion-exchange column at 
a low concentration of salt. There is still some room to optimize the purification protocol: 
(a) perform an expression test varying competent cells and expression conditions (e.g., 
growth temperature, duration, amount of an inducer, amount of L-rhamnose for pLEMO- 
containing cells), (b) wash the protein-bound Ni-NTA resin with a larger volume of 
buffer containing low-concentration imidazole, (c) try a gradient of imidazole 
concentration to wash and elute the protein, (d) use a cobalt-affinity column because its 
binding is known to be more specific toward a His-tag than Ni-NTA, and (e) after trying 
all the above, run the sample through both cation and anion-exchange columns again and 
compare the chromatograms and SDS-PAGE gels. 
 
 
Co-crystallized of HyMraY with the inhibitor UT-17460. 
 
Our collaborator, Michio Kurosu and his group at the University of Tennessee Health 
Science Center has focused on development of novel natural product-based inhibitors of 
MraY. Recently, they developed a novel nucleoside analog, UT-17460, that inhibits the 
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outgrowth of Clostridium difficile spores by targeting MraY with an IC50 value of 0.08 
 
 4.33 M (Mitachi et al., 2018) (Fig. 3.5). A low IC50 value may indicate high binding 
affinity of the compound to HyMraY, so purified protein was co-crystallized with UT- 
17460 via a standard vapor-diffusion method as well as lipidic cubic phase (LCP). For 
the sitting-drop vapor-diffusion method, initial screening of crystallization conditions was 
performed using commercially available sparse matrices, including MemGold, 
MemGold2, Morpheus, Index, and Crystal Screens. Previous efforts of crystallizing 
HyMraY with substrates such as UDP-MurNAc-pentapeptide and/or C10-P, a soluble 
variant of the native lipid substrate, were not successful. However, in the presence of UT- 
17460, crystal formation was robust throughout MemGold and Index in the sitting-drop 
vapor-diffusion method. Some initial crystal hits were mostly rod-shaped in different 
sizes and most of them were in clusters (Fig. 3.6). The crystals were confirmed to have 
UV fluorescence which suggests that, even though both the protein and the inhibitor will 
fluoresce, they are not salt and likely contain minimally HyMraY. 
 
To optimize the crystallization hits, several modifications were introduced. In general, 
initial hits were converted to a grid screen where the pH increases horizontally across a 
24-well tray and precipitant concentration increases vertically across the tray. The design 
goal is to center the original condition in the grid screen and give a wide range of both 
buffer pH and precipitant concentration. At this point, typical optimization utilized the 
hanging-drop vapor-diffusion method with bigger drops (2 L or more) for ease and 
typically it would lead to increases in the size and changes in the shape of the crystals. 
Also, with hanging drops crystals can be formed at the drop edge and can be harvested 
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more easily from precipitate. For example, for the condition that originally contained 
 
0.1 M Tris pH 8.5, 0.1 M potassium chloride, and 39 % PEG 400 (MemGold D7, Fig. 
 
3.6.B), a grid screen was prepared with the pH range 7.9–8.9 and PEG 400 concentration 
35–43 %. Much bigger rod-shaped crystals were formed throughout the grid screen, but 
they were formed in clusters, which was not ideal for collecting X-ray data on (Fig. 
3.7.B). In order to obtain single crystals, one condition was selected from the grid screen 
(0.1 M Tris pH 8.5, 0.1 M potassium chloride, and 35% PEG 400) and 96 different 
reagents from Additive screen (Hampton Research) were added. At the same time, the 
volume-to-volume ratio of the protein to reservoir condition in the drop was varied. The 
ratio change reduced the clustering of crystals, but some split crystals were still observed 
(Fig. 3.7.C). 
 
In the meantime, over 200 crystals were flash frozen in liquid nitrogen, most of them 
without any additional cryoprotectants and shipped to the SSRL BL12‐2. The crystals 
diffracted only out to approximately 9 Å in the best cases (Fig. 3.8). More efforts are 
needed to make single crystals. 
 
 
Expression and purification of MraY from Mycobacterium thermoresistibile (MthMraY). 
Edwards et al. suggests Mth can be a useful Mycobacterium model organism to study M. 
tuberculosis (Mtb) because of following reasons: Mth (a) is thermostable, (b) has 
generally more soluble orthologs, (c) has a similar genome size as that of Mtb, and (d) 
can cause granuloma formation in the lung, which is a hallmark of Mtb infection. 
(Edwards, Liao, Phan, Myler & Grundner, 2012). The sequence alignment between 
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MthMraY and MtbMraY (also called MurX) resulted in 85% identity and 92% 
similarity (Altschul, Gish, Miller, Myers & Lipman, 1990). Together, MthMraY is an 
attractive ortholog to study from the structural perspective. The MthMraY construct 
initially used for small-scale expression test contained a His-tag, SUMO and a linker 
(His6-SUMO-GS5-MthMraY (51.2 kDa). In Nico21(DE3) pLEMO cells, MthMraY was 
significantly expressed at two different induction temperature and with three different 
concentrations of L-rhamnose added (Fig. 3.9). The highest levels of expression were 
when the cells were induced at 22°C in the presence of 0.4 mM L-rhamnose. Using these 
conditions, the MthMraY expression was repeated in a larger scale, the His-tag was 
removed by cleavage with the Ulp1 protease, and further purified (Fig. 3.10). MthMraY 
eluted from a nickel-affinity column with 110 mM imidazole, 150 mM imidazole, and 
200 mM EDTA. Cleavage with Ulp1 was efficient and purification via a cation-exchange 
column and gel-filtration column went well. However, the yield obtained at the end was 
too low to be used for crystallization trials. The obtained protein was used for negative 
staining and imaged sample using a transmission electron microscope (TEM). 
 
MthMraY aggregated in negative stain. 
 
Purified MthMraY (0.014 mg/ml) was applied on a carbon-coated 400-mesh carbon grid 
followed by 2% uranyl acetate. Two different areas of the grid were imaged using a 
Tecnai T12 (120 keVa TEM) at 26,500–67,000x magnification (Fig. 3.11). Some 
aggregation of particles was observed possibly due to the presence of excess decyl 
maltoside (DM) micelles. 
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Crystallization of MurG from Hydrogenivirga sp. (Hy) with UDP-GlcNAc. 
 
A construct of MurG from Hydrogenivirga sp. 128–5-R1–1 (HyMray) was generated 
with a His-tag followed by a thrombin cleavage site before the start of the protein. The 
construct, His6-thrombin-HyMurG, was expressed in E. coli cells and purified in two 
steps by a cobalt-affinity column and a gel-filtration column from either the cytosolic 
fraction or that obtained by extraction from the membrane pellet (Fig. 3.12). The 
HyMurG extracted from the E. coli membrane pellet resulted in pure and homogeneous 
protein and confirms the expectation that HyMurG is strongly associated with the 
membrane. Purified protein was incubated with UDP-GlcNAc, the soluble substrate, and 
screened for crystallization conditions. Four commercial screens were initially tried and 
among them, four conditions produced initial crystal hits (Fig. 3.13). 
 
 
Grid screens with varying buffer pH and precipitant concentration were set up for all of 
the initial four conditions. One condition, MemGold F12, reproduced crystals with 
improved size and shape in hanging-drop vapor-diffusion method. Furthermore, 
microseeds were prepared from older crystal trays and used for setting up new trays with 
fresh protein/substrate solution. Several hundreds of rod-shaped crystals were shipped to 
the SSRL BL12‐2. Four data sets that are worth reporting here have resolution cut-off of 
3.28 Å, 2.81 Å, 2.78 Å, and 2.60 Å based on thresholds I followed with overall 
completeness higher than 99 % (over 70 % in the highest resolution shell), intensity (I/σ) 
close to or bigger than 1, and correlation coefficient value from random half-datasets 
(CC1/2) over 40 %. The first data set cut off at 3.28 Å was solved using a molecular 
replacement with a search model of MurG from Pseudomonas aeruginosa (PDB ID: 
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3S2U), followed by three rounds of refinement, resulting in Rwork = 0.3837 and Rfree = 
0.4494. Although seeing a positive Fo-Fc map in the region UDP-GlcNAc is likely to fit 
based on the secondary structure alignment with PaMurG bound to UDP-GlcNAc is 
exciting, there were other problems including high clash score and high number of 
outliers of the Ramachandran plot. Based on the same criteria mentioned above, the next 
three data sets were cut off at resolution of 2.81 Å (Fig. 3.14.AB), 2.78 Å (Fig. 3.14.CD) 
and 2.60 Å (Fig. 3.14.EF). Phases of the 2.60 Å data set were solved by the same search 
model mentioned above and currently model building and refinement are in progress 
(Fig. 3.15). 
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DISCUSSION 
 
For peptidoglycan biosynthesis, one of the remaining questions that are challenging to 
address is how undecaprenyl phosphate (C55-P) is incorporated into the active site of 
MraY at the cytoplasmic side and how it interacts with UDP-MurNAc-pentapeptide to 
produce Lipid I. In addition, how Lipid I, that is hydrophobic in nature, is transferred to 
the MurG active site and transfers a GlcNAc to produce Lipid II. In order to understand 
the occupancy of the lipid substrates and products in the active sites, structure 
determination of the enzymes in complex with both of the substrates is required. 
 
 
Structures of MraY in complex with any of the substrates have not been determined. In 
collaboration with the Kurosu laboratory, MraY from the thermophile, Hydrogenivirga 
sp., was co-crystallized with a substrate analog (Fig. 3.16.A). However, the crystals 
obtained had low diffraction quality (data not shown here). One of the inhibitor 
compounds the Kurosu laboratory developed, UT-17460 (Fig. 3.5), was also used to co- 
crystallize with HyMraY. UT-17460 is expected to bind to MraY in a similar way as 
UDP-MurNAc-pentapeptide does via the uridine. The presence of UT-17460 enhanced 
crystallization of HyMraY, but the highest resolution obtained the diffraction data was 8 
Å. Previously, solubility of UT-17460 in solution was low, but it was improved by 
preparing it in a salt form by the Kurosu laboratory and renamed as aminouridyl 
phenoxypiperidinbenzyl butanamide (APPB) (Fig. 3.16.B). Co-crystallization with APPB 
 
produced similar crystals as before, but the diffraction quality stayed the same. 
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Unlike MraY, crystal structures of MurG from E. coli and Pseudomonas aeruginosa in 
complex with its soluble substrate, UDP-GlcNAc, are available. Lipid I- or Lipid II- 
bound structures of MurG, however, has not been determined. MurG from Hyrogenivirga 
sp. was expressed and purified in high yield and homogeneity from the E. coli membrane 
pellet. Co-crystallization and high-resolution diffraction data collection of HyMurG with 
UDP-GlcNAc has been successful. The next goal is co-crystallizing MurG with a soluble 
analog, C10-P, or MraY with its substrates. 
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Figure 3.1. Summary of the peptidoglycan biosynthesis pathway. Peptidoglycan biogenesis starts with uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc), which is converted to UDP-N-acetylmuramyl pentapeptide (UDP- 
MurNAc-pentapeptide) by a series of enzymes, MurA-F. MraY catalyzes the transfer of phospho-MurNAc- 
pentapeptide to undecaprenyl phosphate (C55-P), forming Lipid I. MurG adds a GlcNAc to produce Lipid II, which is 
then flipped to the periplasmic side and undergoes polymerization and cross-linking to synthesize the peptidoglycan 
layer. Inhibitors and phage proteins that target specific enzymes in the pathway are shown in orange and green, 
respectively. PEP, phosphoenolpyruvate; NADPH, nicotinamide adenine dinucleotide phosphate. Created by Prof. Bil 
Clemons. 
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Figure 3.2. Optimized purification of HyMraY. A, an SDS-PAGE gel from a nickel-affinity column run with 
HyMraY. HyMraY came off in W4, E1, and E2 fractions. FT2, second flow-through; W1–2, wash with 20 mM 
imidazole and 10 mL each; W3–4, wash with 20 mM EDTA and 10 mL each; E1–4, elute with 20 mM EDTA and 5 
mL each; the last lane is Broad Range protein marker in kDa from Bio-Rad; B, purification of HyMraY using a cation-
exchange column. Left, a cation-exchange (Uno S6) chromatogram shows HyMraY (peak at ~55 mL) is separated 
from other contaminants based on charge difference. Right, fractions 24–40 were run on an SDS-PAGE gel and 
HyMraY is almost pure; C, purification of HyMraY using a gel-filtration column. Left, a gel-filtration (Superdex 200 
16/600) chromatogram shows a symmetrical peak of HyMraY. Right, fractions 16–27 were run on an SDS-PAGE gel 
and HyMraY is pure. 
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Figure 3.3. Cleavage of the His-tag from HyMraY and purification via an anion-exchange column. A, an SDS- 
PAGE gel from a nickel-affinity column run with HyMraY. HyMraY came off in W3-W4 and E1-E2 fractions. FT2, 
second flow-through; HS, high-salt wash with 1 M NaCl and 5 mM imidazole and 50 mL; W1–5, wash with 20 mM 
EDTA and 10 mL each; E1–3, elute with 200 mM EDTA and 5 mL each; the first lane is Broad Range protein marker 
in kDa from Bio-Rad; B, a SDS-PAGE gel after 3C proteolysis. Before, before adding HRV 3C protease to the protein 
sample; 1 day, cleavage for 1 day; 2 days, cleavage for 2 days. C, purification of HyMraY without the His-tag using an 
anion- exchange column. Left, an anion-exchange (Uno Q6) chromatogram shows HyMraY came off pure in the first 
smaller peak. Right, fractions 19–26 were run on an SDS-PAGE gel and HyMraY is pure in fractions 19–21; D, 
purification of HyMraY without the His-tag using a gel-filtration column. Left, a gel-filtration (Superdex 200 10/300) 
chromatogram shows an almost symmetrical peak of the protein. The red circle indicates the fractions from the first 
peak in C. Right, fractions 12–19 were run on an SDS-PAGE gel and HyMraY without the His-tag is pure. Before, the 
sample before adding HRV 3C protease was run to confirm cleavage again. E, Left, a gel-filtration (Superdex 200 
10/300) chromatogram shows a peak with a left shoulder. Right, fractions 11–20 were run on an SDS-PAGE gel and 
HyMraY without the His-tag is pure. The blue circle indicates the fractions from the second peak in C. 
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Figure 3.4. Cleavage of the His-tag from HyMraY and purification via a cation-exchange column. A, an SDS- 
PAGE gel from a nickel-affinity column run with HyMraY. HyMraY came off mostly in W2. FT2, second flow-
through; HS, high-salt wash with 1 M NaCl and 5 mM imidazole and 50 mL; W1–4, wash with 20 mM EDTA and 10 
mL each; E1–4, elute with 200 mM EDTA and 5 mL each; the first lane is Broad Range protein marker in kDa from 
Bio-Rad; B, a SDS-PAGE gel after 3C proteolysis. Before, before adding HRV 3C protease to the protein sample; 3 
days, cleavage for 3 days. C, purification of HyMraY without the His-tag using a cation-exchange column. A cation-
exchange (Uno S6) chromatogram shows HyMraY came off fairly pure in fractions 24–34. D, HyMraY without the 
His-tag using a gel- filtration column. Left, a gel-filtration (Superdex 200 10/300) chromatogram shows an almost 
symmetrical peak. 
Before, the sample before adding HRV 3C protease was run to confirm cleavage again. Fraction 7–16 was run on 
an SDS-PAGE gel. 
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Figure 3.5. The development of UT-17460. The existing antibiotic, FR-900493 from Bacillus cereus (left), was 
chemically modified and became UT-17460 (right) that has improved inhibitory activity against HyMraY (IC50 = 0.08 
 4.33 M). This figure is adapted from the published work in collaboration with the Kurosu lab (Mitachi et al., 2018). 
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Figure 3.6. Initial crystal hits of HyMraY with UT-17460 from commercial screens. A, 0.2 M sodium acetate 
trihydrate, 0.2 M potassium chloride, 0.1 M HEPES pH 7.0, 22% PEG 3000; B, 0.1 M Tris pH 8.5, 0.1 M potassium 
chloride, 39% PEG 400; C, 0.2 M sodium chloride, 0.1 M Bis-Tris pH 5.5, 25% PEG 3350; D, 0.05 M ammonium 
sulfate, 0.05 M Bis-tris pH 6.5, 30% Pentaerythritol ethoxylate (15/4 EO/OH). A&B from MemGold (Molecular 
Dimensions). C&D from Index (Hampton Research).Each tick of the ruler in the images is 4 m long. 
A B 
C D 
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Figure 3.7. Optimization of a crystal condition of HyMraY with UT-17460. A, an initial crystal hit from MemGold 
in 0.1 M Tris pH 8.5, 0.1 M potassium chloride, and 39% PEG 400 via the sitting-drop vapor-diffusion method with a 
0.4 L drops. B, pH was optimized to 8.9 in the  hanging-drop vapor-diffusion method with 2 L drops. C, the PEG 
400 concentration was optimized to 35% in the hanging-drop vapor-diffusion method with 2 L of the sample and 1 L 
of the well solution in each drop. An additive, 0.03 M glycyl-glycyl-glycine was also added to the well and the drop. 
A B 
C 
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Figure 3.8. X-ray diffraction screening of HyMraY co-crystallized with UT-17460 from the grid screen at the 
SSRL BL12-2. A&B, The final concentration of the protein and UT-17460 in the drop was 5 mg/ml and 500 µM, 
respectively. The crystallization condition was 0.1 M Tris pH 8.7, 0.1 M potassium chloride, and 43% PEG 400. Note, X-
ray screening on Nov. 8, 2018; the cassette number was 333; the port number was E5. C&D, The final concentration of 
the protein and UT-17460 in the drop was 2.6 mg/ml and 500 µM, respectively. The crystallization condition was 0.1 M 
Tris pH 8.3, 0.1 M potassium chloride, and 43% PEG 400. Note, X-ray screening on Nov. 19, 2018; the cassette 
number was 210; the port number was E6. E&F, The final concentration of the protein and UT-17460 in the drop was 
2.6 mg/ml and 500 µM, respectively. The crystallization condition was 0.1 M Tris pH 8.3, 0.1 M potassium chloride, 
and 39% PEG 400. Note, X-ray screening on Nov. 19, 2018; the cassette number was 210; the port number was D6. 
The crystals harvested are shown in A, C, and E at the top left corner. A and B/ C and D/ E and F are pairs of diffraction 
images that were acquired from exposing the crystals 90° apart. The resolution rings were drawn in using Adxv. 
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Figure 3.9. Expression test of MthMraY. A, the His6-SUMO-GS5-MthMraY construct was expressed in 
Nico21(DE3) pLEMO cells in the presence of 0.2, 0.4, or 0.6 mM L-rhamnose and they were induced at either 30 C or 
22 C. The His6-HyMraY was expressed as a control. U, uninduced; I, induced. A, an SDS-PAGE gel shows both 
HyMraY and MthMraY were expressed in all conditions. B, a Western blot against -His5 antibody shows MthMraY is 
clearly expressed in all of the induced fractions. The reason MraY does not appear in the Western blot is due to 
inaccessibility of the His-tag in this construct. 
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Figure 3.10. Cleavage of the His-tag and purification of MthMraY. A, an SDS-PAGE gel from a nickel-affinity 
column run with MthMraY. MthMraY came off in W4–6 and E1–4 fractions. FT, flow-through; W1, wash with 20 mM 
imidazole and 10 mL each; W2, wash with 30 mM imidazole and 10 mL each; W3, wash with 50 mM imidazole and 
10 mL each; W4, wash with 80 mM imidazole and 10 mL each; W5, wash with 110 mM imidazole and 10 mL each; 
W6, wash with 150 mM imidazole and 10 mL each; E1–4, elute with 200 mM EDTA and 5 mL each; the first lane is 
Broad Range protein marker in kDa from Bio-Rad; B, cleavage of the His-tag off MthMraY using Ulp1 and a reverse 
nickel-affinity column. C, Left, a cation-exchange (Uno S6) chromatogram shows multiple peaks. Right, fractions 26–
34 run on an SDS-PAGE gel confirm MthMraY was present; D, purification of MthMraY using a gel-filtration 
(Superdex 200 10/300) chromatogram shows multiple peaks. An SDS-PAGE gel was run and faint bands at the right 
size of MthMraY appeared in fraction 13–14 (not shown here). 
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Figure 3.11. Micrographs of negative-stained MthMraY on a carbon-coated copper grid. MthMraY purified in 
DM on a carbon-coated 400-mesh copper grid is stained with 2% uranyl acetate. A, the scale bar is 50 nm long; B, the 
scale bar is 100 nm long. A Tecnai T12 was used to image the grid. 
A B 
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Figure 3.12. Purification of MurG from Hydrogenivirga sp. A, An SDS-PAGE gel from a cobalt-affinity column. 
Most HyMurG came off in E1–6 fractions. FT2, second flow-through; HS, high-salt wash, wash with 1 M NaCl and 50 
mL; W1–5, wash with 30 mM imidazole and 10 mL each; E1–6, elute with 200 mM imidazole and 5 mL each; the first 
lane is Broad Range protein marker in kDa from Bio-Rad; B, purification of HyMurG using a gel-filtration column. 
Left, a gel-filtration (Superdex 200 10/300) chromatogram shows a symmetrical peak of HyMurG. Right, fractions 13–
16 were run on an SDS-PAGE gel and HyMurG was pure. 
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Figure 3.13. Initial crystal hits of HyMurG co-crystallized with UDP-GlcNAc. A, 0.2 M sodium malonate, 20 % 
PEG 3350 pH 7.4 (Index H3); B, 1.2 M sodium citrate tribasic dehydrate, 0.01 M Tris pH 8.0 (MemGold A2); C, 0.1 M 
ADA pH 7.0, 31 % PEG 600 (MemGold2 H3); D, 0.07 M sodium chloride, 0.05 M sodium citrate pH 4.5, 22 % PEG 
400 (MemGold F12). 
A B 
C D 
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Figure 3.14. 2.81 Å, 2.78 Å, and 2.60 Å X-ray diffraction images of HyMurG co-crystallized with UDP-GlcNAc at 
the SSRL BL12-2. The final concentration of the protein and UDP-GlcNAc in the drop was 5.5 mg/ml and 5.0 mM, 
respectively. The crystallization condition for A-D was 0.05 M sodium citrate pH 5.3, 0.07 M sodium chloride, and 22 
% PEG 400. The crystallization condition for E and F was 0.05 M sodium citrate pH 5.5, 0.07 M sodium chloride, and 
21 % PEG 400. The crystals that were harvested without additional cryoprotectant and exposed to X-ray are shown in 
the top left corner of A, C, and E. A and B/ C and D/ E and F are pairs of diffraction images that were acquired from 
exposing the crystal 90° apart. The data set collected from A and B diffracted to 2.81 Å, that from C and D to 2.78 Å, 
and that from E and F to 2.60 Å. The resolution rings were drawn in using Adxv. Note. X-ray screening for A-D on 
March 26, 2019; the cassette number was 379; the port number was A2 and A3. X-ray screening for E-F on May 3, 2019; 
the cassette number was 203; the port number was B7. 
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Figure 3.15. Partially refined 2.60 Å X-ray diffraction data of HyMurG reveals some electron density for UDP- 
GlcNAc. The search model used to solve phases of the diffraction data was MurG from Pseudomonas aeruginosa bound 
to UDP-GlcNAc (PDB ID: 3S2U). Refined HyMurG structure reveals a positive Fo-Fc map (green) in the center of the 
image, which is likely to be where UDP-GlcNAc binds. 
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Figure 3.16. Chemical structures of the S-analog of UDP-MurNAc-pentapeptide in a diastereomer mixture and 
APPB-HCl salt. A, The Kurosu laboratory synthesized the S-analog and purified using a HPLC HYPERSIL GOLDTM 
column with the solvent ratio of MeCN : 0.05 M NH4HCO3 (aq) = 5 : 95 and 2.0 mL/min flow rate. The product was 
detected at 254 nm. B, UT-17460 was renamed with aminouridyl phenoxypiperidinbenzyl butanamide (APPB) and 
solubility was improved. 
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Table 3.1. Statistics of X-ray data collection of HyMurG co-crystallized with UDP-GlcNAc at 2.60 Å. Values in 
parenthesis are from the highest resolution shell. 
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MATERIALS AND METHODS 
 
Expression and purification of HyMraY 
 
The pET22b-His6-HyMraY plasmid was transformed into Nico21(DE3) pLEMO cells the 
night before expression. In the morning of the expression day, all the colonies from a 
plate were scraped off and added to a small culture flask with 200 mL of LB + 35 µg/ml 
carbenicillin for a few hours. Then, 1 L 2x yeast tryptone (YT) (16 g/L tryptone, 10 g/L 
yeast extract, and 5 g/L NaCl) media and 35 µg/ml carbenicillin was inoculated with 
approximately 10 mL of the starter culture in the presence of 0.4 mM L- rhamnose. The 
cells grew at 37C and when optical density at 600 nm (OD600) reaches 0.4, the 
temperature was decreased to 30C. When OD600 becomes 0.6–0.7, the cells were 
induced with 0.4 mM isopropyl-β-1-thiogalactopyranoside (IPTG) and grown for four 
more hours. The culture was harvested using a JLA-8.1 rotor at 4,000 rpm for 15 min. 
 
 
Cell pellets were resuspended and homogenized into 20 mM Tris pH 7.5, 300 mM NaCl, 
10% glycerol, 5 mM βME, and protease inhibitors (e.g., PMSF, benzamidine). The cell 
resuspension underwent four passes in a microfluidizer. The cell lysate was spun in a 
JLA-16.250 rotor at 12,000 rpm for 30 min to pellet unbroken cells and cell debris. 
Subsequently, the supernatant was spun in an ultracentrifuge Ti-45 rotor at 45,000 rpm 
for 30 min and membrane pellet was scraped off from the bottom of the tubes. The 
membrane pellet was stored at -80C or went forward and was resuspended in 20 mM 
HEPES pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, and protease inhibitors along 
with 1 % DM and 5 mM imidazole. Extraction was achieved for two hours, rocking at 
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4C. The sample was spun in an ultracentrifuge Ti-50.2 rotor at 45,000 rpm for 30 min, 
from which the supernatant was saved and incubated with Ni-NTA resin (1 mL resin was 
used for the sample from 6 L culture.) overnight, rocking at 4C. 
 
The sample bound to the Ni-NTA resin was first washed with 20 CV of 20 mM HEPES 
pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, 0.15 % DM, and 20 mM imidazole, 
which was followed by another 20 CV wash with the same buffer, except for 20 mM 
EDTA instead of 20 mM imidazole. Then, proteins were eluted in 5 mL fractions of 20 
CV with 20 mM HEPES pH 7.5, 100 mM NaCl, 10 % glycerol, 5 mM βME, 0.15 % DM, 
and 200 mM EDTA. All of the fractions from the nickel-affinity column were run in an 
SDS-PAGE gel. The fractions with proteins were concentrated using an Amicon 50 kDa 
cut-off concentrator (Millipore) until the volume reached about 5 mL. Then, the sample 
was added to a 10 kDa cut-off SnakeSkinTM dialysis tubing (Thermo Scientific) and 
dialyzed in 1 L of 20 mM HEPES pH 7.5, 10 mM NaCl, 10 % glycerol, 5 mM βME, and 
0.15 % DM overnight at 4C. 
 
 
On the next day, the dialyzed sample was filtered and injected into a cation-exchange 
column (Uno S6 from Bio-Rad) connected to a FPLC (BioLogic DuoFlow v5.3 from 
Bio-Rad). Proteins were released from the column during a gradient from 100 % Buffer 
A (same as the dialysis buffer) to 65 % Buffer B (same as Buffer A except for 1 M 
NaCl). Fractions in the peak area were run on an SDS-PAGE gel. The fractions with pure 
protein was concentrated using a concentrator to be injected onto a pre-equilibrated gel-
filtration 
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column (Superdex 200 16/600 (GE Healthcare)) in a buffer containing 20 mM HEPES 
pH 7.5, 150 mM NaCl, 10 % glycerol, 0.15 % DM, 5 mM βME, and 10 mM MgCl2 at 0.7 
mL/min. The protein eluted at approximately 65 mL and fractions were analyzed by 
SDS-PAGE and Coomassie staining. The final step was pooled fractions that were 
concentrated and either used immediately for structural and biochemical studies or flash 
frozen in liquid N2 and stored at -80C. 
 
Purification of HyMraY without a His-tag 
 
The construct His-3C-HyMraY (pET22b-His6-3C (Leu-Glu-Val-Leu-Phe-Gln ↓ Gly-Pro)- 
GS5-HyMraY (42.6 kDa)) was expressed as described above for HyMraY. Ni-NTA resin 
(1 mL resin for 6 L culture) was incubated with the extracted sample overnight at 4C, 
rocking. The bound sample was washed with 50 CV of 20 mM HEPES pH 7.5, 1 M 
NaCl, 10 % glycerol, 0.15 % DM, 5 mM βME, 5 mM imidazole, and protease inhibitors, 
followed by 50 CV of the same buffer, except for 300 mM NaCl, and 20 mM EDTA. 
Then, the proteins were eluted in three fractions of 5 mL each with the buffer containing 
150 mM NaCl and 200 mM EDTA. W3–4 and E1–2 were collected and dialyzed into 50 
mM Tris pH 7.5, 150 mM NaCl, 10 % glycerol, 5 mM βME, and 0.15 % DM at 4C for 
one day. HRV 3C protease (2 units/L; ThermoFisher Scientific) was added to the 
dialyzed sample and rocked at 4C for about two days with the ratio of the protease (60 
µL) : protein (9 mg) = 1: 150. A reverse nickel-affinity column was run after incubating 
the digested sample with Ni-NTA resin at 4C, overnight. The flow-through was taken 
from the reverse nickel-affinity column and dialyzed to run on an anion-exchange column 
74 
 
(Uno Q6) with Buffer A (20 mM HEPES pH 7.5, 10 % glycerol, 5 mM βME, and 0.15 
 
% DM) and Buffer B, containing1 M NaCl. Lastly, selected fractions from the anion-
exchange column were run on a gel-filtration column (Superdex 200 10/300) with the 
buffer containing 150 mM NaCl and 10 mM MgCl2. 
 
 
For subsequent expression, the same plasmid was expressed again and its His-tag was 
cleaved using the ratio of HRV 3C protease (28 µL) : protein (2.8 mg) = 100 :1. Then, the 
sample was purified in the same process as above, except for using a cation (Uno S6) 
instead of anion-exchange column. All the buffer compositions stayed the same. 
 
 
Co-crystallization of HyMraY with UT-17460 using vapor-diffusion method and lipidic 
cubic phase (LCP) 
For initial crystallization screening, 1 mM UT-17460 was added to 5 mg/ml purified 
HyMraY. Aggregates were removed from the mixture on Amicon 0.22 m filter by 
spinning at 8,000 rpm for 5–15 min at 4C. For the standard sitting-drop vapor-
diffusion method, the sample (0.2 L) was dispensed into individual wells on Swissci 
96-well MRC plates (Molecular Dimensions), followed by well solution (0.2 L), 
which was drawn from the 50 L reservoir, using Mosquito (TTP Labtech). Some 
commercial sparse matrices used were MemGold (Molecular Dimensions), MemGold2 
(Molecular Dimensions), Morpheus (Molecular Dimensions), Index (Hampton 
Research), and Crystal Screens (Hampton Research). 
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Crystallization conditions that gave initial crystal hits were usually categorized as a 
buffer with specific pH, salt, and a precipitant reagent. A grid screen was designed by 
varying pH and precipitant concentration around the condition in which crystals were 
observed, as salt concentration was kept constant. For grid screens, hanging drops were 
used and the volume increased in the drop by adding 1 µL of protein sample that contains 
UT-17460 and 1 µL of well solution. As optimization continues, a finer range of pH and 
precipitant concentration were used, the volume ratio of protein sample to condition that 
go into drop varied, and the whole drop size was varied. Also, a 96-well Additive screen 
(Hampton Research) was used to see if any of the additives improve the size and change 
the shape of crystals. 
 
 
The initial crystallization screening for the LCP method started with mixing 8 mg/ml 
purified HyMraY in addition of 1 mM UT-17460 and monoolein (sigma) to 1:2, 2:3, 4:5 
volume-to-volume ratio using a syringe lipid mixer. The protein/lipid mixture was 
dispensed on a glass plate using a Gryphon (Art Robbins Instruments). The volume ratios 
of the sample to crystallization condition used were 0.05 µL to 0.8 µL, 
0.05 µL to 1 µL, 0.1 µL to 1 µL, 0.15 µL to 1 µL, and 0.2 µL to 1 µL. Two commercial 
sparse matrices, MemMeso (Molecular Dimensions) and MemGoldMeso (Molecular 
Dimensions), were used. The plates were stored at room temperature. 
 
 
Expression and purification of MthMraY 
 
The pET22b-His6-SUMO-GS5-MthMraY plasmid was transformed into the Nico21(DE3) 
pLEMO competent cells. The colonies were grown at 37°C until OD600 reaches 0.4 and 
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the flasks were transferred to 22°C. When OD600 reaches 0.6–0.8, the cells were 
 
induced with 0.4 mM IPTG and grown overnight. The cells were harvested using a JLA- 
 
8.1 rotor at 4,000 rpm for 15 min and resuspended in lysis buffer (20 mM Tris pH 7.5, 
300 mM NaCl, 10 % glycerol, 5 mM βME, and protease inhibitors). The cells were lysed 
by flowing through a microfluidizer for four times. The lysate was spun down in a JLA- 
16.250 rotor at 12,000 rpm for 30 min. Pellets were discarded and the supernatant was 
spun down in a Ti-45 rotor at 45,000 rpm for 30 min. 
 
 
The membrane pellets were either stored at -80°C or resuspended in an extraction buffer 
(20 mM HEPES pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, 10 mM imidazole, 
1 % DM, and protease inhibitors). Solubilized membrane fraction was incubated for 2 
hours at 4°C and spun down in a Ti-50.2 rotor at 45,000 rpm for 30 min. Pellets were 
discarded and the supernatant was incubated with 2.5 mL Ni-NTA resin (for 6L culture) 
overnight at 4°C. The sample was applied to a gravity column, washed with an imidazole 
gradient covering 20 mM, 30 mM, 50 mM, 80 mM, 110 mM, and 150 mM imidazole- 
containing buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, 
 
0.15 % DM) and eluted with the similar buffer that contained 100 mM NaCl and 200 mM 
EDTA. The fractions were run on a SDS-PAGE gel, collected and dialyzed into 1 L of 20 
mM Tris pH 7.5, 100 mM NaCl, 10 % glycerol, 1 mM DTT, and 0.15 % DM overnight at 
4°C. Ulp1 (expressed and purified in the lab) was added to the dialyzed sample and 
incubated for one day at 4°C. Then, the sample was incubated with the 2.5 mL Ni-NTA 
resin overnight at 4°C. A reverse nickel-affinity column was performed by collecting the 
flow-through that contained the protein without a tag and washing the sample with 20 
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mM HEPES pH 7.5, 300 mM NaCl, 10 % glycerol, 0.15 % DM, 5 mM βME, and 30 
mM imidazole. The rest of the sample was eluted with the sample buffer containing 200 
mM EDTA. An SDS-PAGE gel was run to make sure the sample with no tag came off 
in the flow-through. 
 
 
The tag-free protein was dialyzed into Buffer A (20 mM HEPES pH 7.5, 10 mM NaCl, 
10 % glycerol, 5 mM βME, and 0.15 % DM) overnight at 4°C and ran on a cation-
exchange column (Uno S6) with a gradient of 100 % Buffer A to 100 % Buffer B, 
containing 1 M NaCl. After an SDS-PAGE gel was run, the sample was run on a gel- 
filtration column (Superdex 200 10/300) with a running buffer, 20 mM HEPES pH 7.5, 
150 mM NaCl, 10 % glycerol, 0.15 % DM, 5 mM βME, and 10 mM MgCl2. Fractions 
were analyzed by SDS-PAGE and Coomassie staining and the fractions with pure protein 
were collected and concentrated. 
 
 
Preparation of negative-stained grids of MthMraY 
 
2 µL of purified MthMraY (0.014 mg/ml) was added to a 400-mesh copper grid that was 
carbon coated using a Cressington 208carbon and glow discharged using an Emitech 
K100X (15 mA, 1 min). After 50 seconds, the excess protein sample on the grid was 
removed using Whatman No. 1 filter paper. Then, 2 µL of 2 % uranyl acetate was added 
on top. After 50 seconds, the excess was again blotted away at the edge of the filter 
paper. 
 
 
Imaging a negative-stained grid of MthMraY using a 120 keV TEM 
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A Tecnai T12 equipped with an electron gun, LaB6, and Gatan Ultrascan 2k x 2k CCD 
was used to image the negative-stained grid of MthMraY. The 26,500- 52,000 
magnification was used to visualize particles. 
 
 
Expression and purification of HyMurG 
 
The pET33b-His6-thrombin (Leu-Val-Pro-Arg ↓ Gly-Ser)-HyMurG plasmid was 
transformed into the Nico21(DE3) competent cells. The cells were grown at 37°C, shaking 
and induced with 0.4 mM IPTG when OD600 reached 0.6–0.8. After growing for four more 
hrs, cells were harvested using a JLA-8.1 rotor at 4,000 rpm for 20 min and resuspended in 
lysis buffer (20 mM Tris pH 8.0, 150 mM NaCl, 10 % glycerol, 5 mM βME, and protease 
inhibitors). The cells were lysed by flowing through a microfluidizer for three times. The 
lysate was spun down in a JLA-16.250 rotor at 12,000 rpm for 30 min. Pellets were 
discarded and the supernatant was spun down in a Ti-45 rotor at 45,000 rpm for 30 min. 
The membrane pellets were either stored at -80°C or resuspended in an extraction buffer 
(20 mM HEPES pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, 10 mM imidazole, 1 
% DM, and protease inhibitors). It was incubated for 2 hours at 4°C and spun down in a Ti- 
 
50.2 rotor at 45,000 rpm for 30 min. Pellets were discarded and the supernatant was 
incubated with 1 mL cobalt resin (for 6L culture) for 2 hrs at 4°C, rocking. The sample was 
flown through a gravity column and washed with 50 CV of 20 mM HEPES pH 7.5, 1 M 
NaCl, 10 % glycerol, 10 mM imidazole, 0.15 % DM, 5 mM βME, and protease inhibitors, 
50 CV of the same buffer with 300 mM NaCl and 30 mM imidazole and eluted with 150 
mM NaCl and 200 mM imidazole. After the sample was checked for purity by SDS-PAGE 
and Coomassie staining, the sample was injected onto a gel-filtration column (either 
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Superdex 200 10/300 or 16/600) with 20 mM Tris pH 7.5, 150 mM NaCl, 10 % glycerol, 
 
0.15 % DM, and 5 mM βME. Fractions from the peak were analyzed by SDS-PAGE, and 
some of the fractions were selected based on the purity for concentration using an Amicon 
50 kDa cut-off concentrator and used for structural studies right away or stored at -80°C. 
 
 
Co-crystallization of HyMurG with UDP-GlcNAc by sitting-drop vapor-diffusion method 
 
6.74 mg/ml HyMurG and 10 mM UDP-GlcNAc were incubated on ice for 30 min, 
filtered, and set up with crystallization conditions in a ratio of one-to-one (0.2 µl + 0.2 µl) 
with a 50-µL reservoir on a 96-well MRC plate using Mosquito. Thus, the final 
concentration of HyMurG and UDP-GlcNAc in the drop was 3.37 mg/ml and 5 mM, 
respectively. Three commercial screens used were Index (Hampton Research), MemGold 
(Molecular Dimensions), and MemGold2 (Molecular Dimensions). The plates were 
stored at room temperature. 
 
 
Optimizing co-crystallization of HyMurG with UDP-GlcNAc using hanging-drop vapor- 
diffusion method 
Initial crystals hits were observed in MemGold F12, MemGold A2, MemGold2 H3, and 
Index H3. Among them, MemGold F12, MemGold A2, and Index H3 conditions were 
used to design 24-well grid screens by varying buffer pH and precipitant concentration. 
5.5–11mg/ml HyMurG and 10 mM UDP-GlcNAc were incubated on ice for 30 min, 
filtered, and set up with crystallization conditions in a ratio of one-to-one (1 µl + 1 µl) 
with a 300-µL reservoir on a 24-well VDX Plate with sealant (Hampton Research). For 
several trays, 0.5 µl microseeds were introduced into each drop. Thus, the final 
80 
 
concentration of HyMurG and UDP-GlcNAc in the drop was 2.7–5.5 mg/ml and 3.6- 
 
5.0 mM, respectively. 
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C h a p t e r 4 
 
 
Structural elucidation of MraY in complex with phage ΦX174 protein E, a novel 
inhibitor to combat antibiotic-resistant Escherichia coli infection 
 
ABSTRACT 
 
Antibiotic- and multidrug-resistant pathogens pose a great threat to public health 
worldwide. Even though Escherichia coli is one of the most studied microorganisms, 
resistance mechanisms of its pathogenic strains are not fully understood. As one way of 
tackling antibiotic-resistant pathogenic E. coli strains, a key integral membrane protein 
called MraY, which is involved in peptidoglycan (PG) biogenesis, has been an attractive 
target for developing antibacterial drugs. Unfortunately, none of the inhibitor compounds 
targeting MraY is in clinical use due to their low cell permeability and cellular 
concentration. MraY is also the target in E. coli for the lysis protein E from a small 
single-stranded bacteriophage ΦX174. However, their molecular interactions have not 
been structurally elucidated. Here, I describe how E. coli MraY in complex with protein 
E was purified, reconstituted in non-detergent systems, and was subject of structural 
studies using X-ray crystallography and electron cryomicroscopy (cryo-EM) single 
particle analysis. The goal of this study is to determine a high-resolution structure of the 
EcMraY-protein E complex and this will pave a way to developing a novel type of anti- 
bacterial drugs. 
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INTRODUCTION 
 
Escherichia coli is a commensal organism in the human gut and uropathogenic E. coli 
(UPEC) is the most common cause of urinary tract infection with emerging antibiotic 
resistance (Flores-Mireles, Walker, Caparon & Hultgren, 2015). A common strategy for 
developing antibacterial drugs is to target the peptidoglycan (PG) that forms a major 
component of the bacterial cell wall. However, UPEC has already shown resistance to 
some β-lactam antibiotics (Blango & Mulvey, 2010) that inhibit penicillin-binding 
proteins (PBPs) preventing cross-linking of the GlcNAc-MurNAc polymer in the 
periplasm (e.g., penicillin, nafcillin, cefadroxil). Blocking enzymes involved in earlier 
steps of the PG synthesis is one way to design new antibacterial agents. A promising 
candidate is MraY, a key integral membrane protein that is essential for cell viability and 
catalyzes the transfer of phospho-MurNAc-pentapeptide from a nucleotide-activated 
form, UDP-MurNAc-pentapeptide, to the lipid carrier, C55-P. 
 
 
Bernhardt et al. provided genetic evidence showing that E. coli MraY is the cellular 
target of protein E, encoded from a single lysis gene in the small single-stranded 
bacteriophage ΦX174 that lyses E. coli cells. (T. G. Bernhardt, Roof & Young, 2000). E- 
mediated lysis requires the host slyD gene, which encodes an FK506 binding protein 
(FKBP)-type peptidyl-prolyl cis-trans isomerase (PPIase). SlyD is thought to stabilize 
protein E, which allows it to be accumulated in the membrane and helps it to lyse E. coli 
cells (Thomas G. Bernhardt, Roof & Young, 2002). Rodolis et al. constructed a helical 
wheel model and proposed the possible interaction site between the transmembrane 
domain of protein E and transmembrane helix 9 of E. coli MraY (Rodolis et al., 2014). In 
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order to confirm the site of action of protein E on EcMraY, determining a high- 
resolution structure of the EcMraY in complex with protein E and EcSlyD is necessary. 
Details of their molecular interactions in the structure will shed light on developing 
protein E as a therapeutic against E. coli. 
 
 
This study discusses our success in expressing and purifying the protein complex that 
contains three protein components (EcMraY, protein E, EcSlyD), followed by how the 
purified protein complex was used for structural characterization using X-ray 
crystallography and cryo-EM single particle analysis. Two constructs that were used are a 
bicistronic vector containing protein E from an isoform of ΦX174, ID21, that has a His- 
tag at the C-terminus and E. coli MraY and the other vector that contains the first 154 
residues of E. coli SlyD. Protein E from ID21 was chosen as it is shorter (76-residues) 
compared to the 91-residue protein E from ΦX174, while the transmembrane domain is 
conserved. Also, ID21 protein E in the complex contains the mutation, L19F, which was 
reported to bypass the SlyD requirement for E-mediated lysis (T G Bernhardt, Roof & 
Young, 2000) and also recover the cell-lysis activity that was lost in a truncated construct 
of ΦX174 protein E, likely by promoting protein-protein interactions (Tanaka & 
Clemons, 2012). Together, this protein complex will be called EYS21-L19F (protein E, 
EcMraY, EcSlyD; protein E is from ID21 with L19F mutation). 
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RESULTS 
 
Expression and purification of the EYS21-L19F complex. 
 
Two plasmids that contain three components of the EYS21-L19F complex (EcMraY, 
protein E from ID21, and EcSlyD1–154) were co-transformed and expressed in E. coli 
cells. Following cell lysis, membrane pellet was obtained and the protein was solubilized 
with 1% DM (weight-to-volume) containing buffer. The protein complex was purified 
via a nickel-affinity, anion-exchange, and gel-filtration columns (Fig. 4.1). A shoulder on 
the right side of the peak in the gel-filtration chromatogram was observed for some cases 
(Fig. 4.1.C) while the peak was perfectly symmetrical in other cases (Fig. 4.1.D). Note 
that some contaminants that were larger than EcMraY were carried over from the nickel- 
affinity column to gel-filtration column (Fig. 4.1). 
 
 
Co-crystallization of EYS21-L19F with the S-analog of UDP-MurNAc-pentapeptide. 
 
We were provided with an S-analog of UDP-MurNAc-pentapeptide, one of the oxygens 
in the α-phosphate group is replaced by a sulfur (Fig. 4.2), by the Kurosu laboratory at 
the University of Tennessee Health Science Center. EYS21-L19F was co-crystallized 
with this analog with the rationale that it would behave as a substrate without being 
catalyzed. Based on the preliminary testing, when more than 100 µM of the analog was 
added to the reaction of MraY from Hydrogenivirga sp., approximately 10 % inhibition 
was observed (Kurosu laboratory). 
 
While the substrate analog was not tested directly on E. coli MraY, we predicted UDP- 
MurNAc-pentapeptide would bind to EcMraY similar to HyMraY. In the presence of 100 
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µM of the analog, crystal formation was readily obtained int two commercial screens, 
MemGold2 and Morpheus. There were three different crystal morphologies during the 
initial screening with the sparse matrices: cubes, pyramids, and three-dimensional 
trapezoids (Fig. 4.3.A-C). The conditions that produced crystals were varied. During 
diffraction screening, two diffraction images were collected 90° apart on several of the 
crystals with a cube-looking crystal diffracting to 7.4 Å (Fig. 4.4.A) and trapezoid- 
looking crystals to 6.3 Å (Fig. 4.4.B) and 6.6 Å. X-ray diffraction data were remotely 
collected at the SSRL BL12‐2 and data processing was performed using XDS 
(Kabsch, 2010). With all three data sets, XDS suggested the space group number 155 
(H32) with a three-fold symmetry operator. 
Attempts to solve the phases using molecular replacement were not successful using 
Phenix (Adams, Pavel, et al., 2010). 
 
 
Initial crystallization conditions were further optimized by designing and setting up grid 
screens varying buffer pH and precipitant concentration. Switching from sitting-drop to 
hanging-drop vapor-diffusion method with larger drop size also increased the crystal size 
(Fig. 4.3.D-G). Some of the crystals from hanging-drop trays were screened at the APS 
23-ID-B (Fig. 4.5). Unfortunately, most of the crystals appeared to have been kept in the 
trays too long and were likely dehydrated, causing streaky spots on the diffraction 
images or no diffraction at all. After this trip, the EYS21- L19F crystals were not able to 
be reproduced in the presence of the substrate analog for some time. 
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EYS21-L19F in amphipols imaged in negative stain. 
 
Amphipathic polymers (amphipols or Apols) were developed (Tribet, Audebert & Popot, 
1996) as solubilizing agents to replace detergents and stabilize membrane proteins with 
the most popular being Amphipol A8-35. Amphipols wrap around a membrane protein 
stabilizing them in buffer without requiring any detergent. I previously observed that the 
EYS21-L19F sample purified in dodecyl maltoside (DDM) aggregated when it was 
negative-stained and imaged using a TEM, Tecnai T12 operating at 120 keV. I speculated 
that aggregation was possibly coming from excess detergent micelles, I mixed the 
detergent solubilized protein with amphipols and were removed the detergent by using 
beads. The amphipol stabilized protein was injected onto a gel-filtration column 
(Superdex 200 10/300) was run with buffer without any detergent resulting in a nearly 
symmetrical peak (Fig. 4.6.A). The fractions in the peak area were concentrated, 
incubated with the substrate analog, and added to a copper grid, followed by the addition 
of 2 % uranyl acetate. The grid was imaged using a Tecnai T12 and the particles looked 
homogeneous and no other contaminants were detected (Fig. 4.6.BC). The same protein 
sample with the substrate analog was used to prepare a cryo-EM grid and a data set was 
collected from a Talos Arctica operating at 200 keV. Data processing on the collected 
micrographs was initiated with Relion-2 (Kimanius, Forsberg, Scheres & Lindahl, 2016; 
Scheres, 2012), but it was difficult to pick out individual particles and 2D classes were 
not obtained (data not shown here). 
 
 
DDM was selected from a detergent screening for extracting EYS21-L19F. 
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In order to select a detergent that can extract the EYS21-L19F complex as native form 
as possible, detergent screening was performed during the extraction step of purification. 
1 % weight-to-volume amount of each of six detergents, DDM, DM, LDAO, β-OG, Fos- 
choline-12, and Cymal-5, was added to the buffer that was used to resuspend the 
membrane pellet and rocked for two hours at 4 °C. The samples were spun in an 
ultracentrifuge rotor and the supernatant from each detergent-extracted sample was saved 
to incubate with 250 µL of Ni-NTA resin. Six nickel-affinity columns were run in 
parallel and the purity of the fractions were checked by SDS-PAGE (Fig. 4.7.A). The 
amount of EcMraY extracted was similar among DDM-, DM-, and Cymal-5-extracted 
samples, whereas the other three detergent-extracted samples showed thin double bands 
at the size, in which EcMraY is supposed to appear as a smeared band. Elution fractions 
were collected from each nickel column, concentrated, and run on a gel-filtration column 
(Fig. 4.7.BD). The obvious differences were the height of the main peaks, indicating the 
amount of the protein complex extracted, and the size of the shoulders. DDM was the 
best among them because the main peak is the highest, almost symmetrical, and had a 
shoulder only on one side of the peak. Purity of all of the detergent samples from the 
columns was checked by SDS-PAGE with the DDM fractions shown here (Fig. 4.7.C). 
After this screening, DDM instead of DM was used to extract the EYS21-L19F complex 
in the subsequent purification preparations. 
 
 
Optimization of purification of the EYS21-L19F complex. 
 
Previous purification protocol of the EYS21-L19F provided high yield of almost pure 
protein sample, but contaminants that are bigger than EcMraY always appeared on a 
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SDS-PAGE gel after every step of purification (Fig. 4.1). This problem was resolved 
by using a cobalt-affinity instead of nickel-affinity column at the expense of some yield 
(Fig. 4.8.A). The protein complex looks pure on an SDS-PAGE gel after a gel-filtration 
column, but there were two small shoulders on the left side of the peak, indicating purity 
can be improved further (Fig. 4.8.C). Running an anion-exchange column (Fig. 4.8.B) in 
between a metal-affinity and gel-filtration chromatography helped reduce the size of the 
shoulders. 
 
 
Purification of three membrane scaffold protein (MSP) variants. 
 
It has been shown that interactions between membrane proteins and its surrounding lipids 
are important to maintain protein function (Phillips, Ursell, Wiggins & Sens, 2009; 
Saliba, Vonkova & Gavin, 2015; Zhou & Cross, 2013). The nanodisc technology was 
developed to provide a lipid bilayer environment to membrane proteins and has been 
widely used for structural and functional studies of proteins (Denisov & Sligar, 2016, 
2017). Nanodiscs refer to the disc-shape formed when the amphipathic helices of a MSP 
(Bayburt, Grinkova & Sligar, 2002) wrap around phospholipids like a belt. Depending on 
the number of transmembrane helices in a protein of interest and the phospholipids used, 
MSP variants of different lengths are selected and that are compatible with the expected 
diameter of nanodiscs that will solubilize the protein in lipids. Here, three MSP 
containing plasmids, pMSP1D1, pMSP1E3D1, and pMSP2N2, were overexpressed in E. 
coli cells and purified using a nickel-affinity column (Fig. 4.9.ACE) and gel-filtration 
column (data not shown). In the purification process, a His-tag was cleaved off by 
digesting the samples with a TEV 
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protease and then removed via a reverse nickel-affinity column (Fig. 4.9.BDF). 
Purified MSPs were stored at -80°C until they were used for nanodisc assembly. 
Phospholipids selected were DMPC, DMPG, POPC, and POPG because their phase 
transition temperatures are close to room temperature or 4°C, which can be controlled 
easily during assembly. Either single or a pair of phospholipids were used for assembly. 
 
 
Reconstitution and imaging of EYS21-L19F into nanodisc composed of MSP1E3D1 and 
DMPC. 
Reconstitution of EYS21-L19F into nanodiscs was performed by incubating purified 
protein, purified MSP1E3D1, and DMPC in the presence of detergent, sodium cholate, at 
room temperature for an hour. Detergent was removed using polystyrene beads. The 
sample containing proteins reconstituted in nanodiscs were incubated with Ni-NTA resin 
overnight at 4°C. On the next day, a nickel-affinity column was run and what newly 
appeared on an SDS-PAGE gel in addition to the EYS21-L19F complex was MSP1E3D1 
(Fig. 4.10.A). The main purpose of running the protein-nanodisc assembly via a nickel- 
affinity column was to remove all the empty nanodiscs as the His-tag on the EYS21- 
L19F complex would only bind to the resin. Subsequently, the eluates were run through a 
gel-filtration (Superdex 200 10/300) column and the fractions with all components were 
collected for concentration (Fig. 4.10.BC). The peak from the gel-filtration 
chromatogram had two large shoulders that came off after the main peak indicating the 
sample was not completely homogeneous. The purified EYS21-L19F assembled in 
nanodiscs with MSP1E3D1 and DMPC was added to a glow-discharged copper grid and 
negative-stained with 2 % uranyl acetate. The images collected from a Tecnai T12 
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operating at 120 keV showed homogenous particles (Fig. 4.11). The same sample was 
used to prepare cryo-EM grids. 
 
 
Cryo-EM sample preparation and data collection of EYS21-L19F-nanodisc assembly. 
The EYS21-L19F-nanodisc sample was added to a glow-discharged Quantifoil R2/2 grid 
using a Vitrobot by varying blot time (2, 4, 6, 8 sec) and keeping 100 % humidity and -5 
blot force with two different concentrations of the protein sample (4 mg/ml or 0.4 mg/ml). 
Grids were subsequently plunge frozen into liquid ethane that was cooled by liquid 
nitrogen. All of the grids were screened in a Talos Arctica operating at 200 keV and in only 
one grid (0.4 mg/ml, 100% humidity, -5 blot force, 2 sec blot time) were particles present 
in the holes of the grid. The selected cryo-EM grid was used to collect two-day movies at a 
165,000x magnification on a Titan Krios operating at 300 keV. 
 
 
The micrographs collected in this data set was motion corrected using MotionCor2 (S. Q. 
Zheng et al., 2017) implemented in Relion-3 and CTF estimated. Then, 1,089 particles 
were manually picked from 89 selected micrographs (Fig. 4.12.A). Micrographs with no 
particles were manually omitted from the whole data set and 2D classification was 
performed with the manually picked particles (Fig. 4.12.B). Six 2D classes were selected 
and averaged to be used as a template to auto-pick the rest of the particles (Fig. 4.12.C). 
Initial 3D initial models were derived from the picked particles (Fig. 4.12.D). The 3D class 
averages from one or more classes were visualized using Chimera (Pettersen et al., 2004) 
(Fig. 4.13). The resolution of the densities was too low to fit known structural components 
of the protein complex. The expectation is that some of the soluble protein domains would 
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be sticking out of the nanodiscs; yet this density was inconsistent throughout the initial 
models, suggesting this part may be flexible. For future data collection, more particles for 
each orientation would be a goal. 
 
 
Other nanodisc assemblies with different combinations of MSP and phospholipid were 
imaged in negative stain. 
After the cryo-EM data analysis from the first EYS21-L19F-nanodisc assembly was 
assessed, nanodiscs with different combinations of MSPs and phospholipids were prepared. 
EYS21-L19F reconstituted in nanodiscs with MSP1D1 and DMPC was added to a 200- 
mesh copper grid along with 2 % uranyl acetate. The images collected in a Tecnai T12 
showed heterogeneous populations of particles, especially particles that look smaller than 
the expected size of 10–15 nm (data not shown). 
 
 
Next, nanodisc prepared and purified with EYS21-L19F consisted of MSP2N2 and 
DMPC/DMPG. Imaging on a Tecnai T12 after negative staining showed that particles tend 
to clump together with smaller particles still present (data not shown). 
 
The next nanodisc prepared and purified with EYS21-L19F consisted of MSP1E3D1 and 
POPC/POPG (Fig. 4.14). Imaging on a Tecnai T12 after negative staining showed again that 
particles tend to clump together and small circular particles were still present (Fig. 4.15). 
 
 
In an attempt to improve heterogeneity, the nanodisc (POPC/POPG, MSP1E3D1) 
assembly of EYS21-L19F was run on an anion-exchange column (Uno Q6). Three 
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different fractions from the column were individually added to 400-mesh copper grids 
with a carbon layer, stained with 2 % uranyl acetate and they were imaged on a Tecnai 
T12. However, heterogeneity that is seen in Fig. 4.15 did not improve (data not shown 
here). This indicates that the sample was likely heterogeneous in the assembly step and 
could not be purified further by size or charge in nanodisc. Heterogeneity could be due to 
partially pure MSPs and/or mixing two different phospholipids for nanodisc assembly. 
For the former case, I previously combined MSP2N2 purified from soluble and insoluble 
fractions and used it for nanodisc assembly above, while MSP1E3D1 used above was 
purified only from cell debris pellet. However, I obtained mixed results in terms of 
heterogeneity from the nanodiscs with MSP2N2 and MSP1E3D1. For the latter case, I 
started with DMPC to prepare nanodisc assembly, but later I used DMPC/DMPG and 
POPC/POPG. Using two different phospholipids could have caused heterogeneity in the 
samples. 
 
 
Further purification of MSP2N2 for the nanodisc assembly. 
 
The next step taken to achieve homogeneity of nanodiscs was taking individual 1-mL 
fractions of MSP2N2 from a gel-filtration column and using each fraction and either POPC 
or POPG alone to assemble with EYS21-L19F (Fig. 4.16). The compositions of nanodiscs 
tried here were (a) MSP2N2 gel-filtration fraction 11 with POPC, (b) MSP2N2 gel- 
filtration fraction 11 with POPG, (c) MSP2N2 gel-filtration fraction 12 with POPC, (d) 
MSP2N2 gel-filtration fraction 12 with POPG, (e) MSP2N2 gel-filtration fraction 13 with 
POPC, and (f) MSP2N2 gel-filtration fraction 13 with POPG. For this preparation, the 
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nanodisc assemblies were not run through another gel-filtration column to remove empty 
nanodiscs. From negative-stain imaging of these assemblies on a Tecnai T12 (Fig. 4.17) 
there was more clumping of particles when MSP2N2 gel-filtration fraction 11 was used, 
whereas smaller particles were clearly observed when fraction 13 was used. The difference 
in the samples prepared from either POPC or POPG was not very obvious and 
inconclusive. This could be due to inconsistent coverage of carbon coating that was 
manually introduced to the grids. Nevertheless, the best grid among them was from the 
nanodisc assembly with MSP2N2 gel-filtration fraction 12 and POPC (Fig. 4.17.C). 
 
 
Further optimization of crystals of EYS21-L19F with the S-analog. 
 
In efforts to reproduce crystals previously acquired (Fig. 4.3), grid screens with a broad 
range of pH and precipitant concentrations were attempted using the prior conditions that 
gave crystals for the EYS21-L19F complex incubated with the analog. However, crystals 
with sharp edges were no longer observed. In the meantime, the purification protocol of the 
EYS21-L19F complex was optimized as described above. The final buffer salt 
concentration was also considered by lowering NaCl concentration (25, 50, 75 mM) for the 
gel-filtration column. In comparison to 100 mM NaCl-containing buffer that had initially 
been used, as NaCl concentration decreases, the sample comes off the column slightly 
faster (Fig. 4.18). The main protein peak is present across the various NaCl concentration, 
whereas the peak is missing when no NaCl is used (Fig. 4.18). 
 
 
Subsequently, more EYS21-L19F was purified in the final buffer with 25 mM NaCl, 
incubated with the analog for 30 min on ice, and trays were set up using several 
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commercially available sparse matrix screens by the sitting-drop vapor-diffusion method. 
Among them, crystals were finally reproduced in either pyramid- or cube-shape, although 
they appeared much smaller than before. The conditions that crystallized the protein 
complex were MemGold2 D5, F3, F7, G1, H2, and Index H2, H3, H10. For some of 
these, grid screens with a range of buffer pH and precipitant concentration were designed 
and set up using the hanging-drop vapor-diffusion method. Among them, we were able to 
consistently reproduce crystals in the grid screens of MemGold F7 (0.1 M MES pH 6.5, 
0.37 M potassium nitrate, 22 % PEG 400) and G1 (0.05 M HEPES pH 6.5, 0.5 M 
potassium chloride, 20 % PEG 400). Several hundreds of crystals were frozen and shipped 
to the SSRL BL12-2 and some X-ray diffraction data sets were collected. The best data set 
diffracted to 4.20 Å (Fig. 4.19 and Table 4.1). 
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DISCUSSION 
 
Determining a high-resolution structure of the EYS21-L19F complex had been a 
challenge, and this could be due to many reasons. This study discussed some 
modifications introduced to the purification process and new approaches to overcome 
various issues. First, some high molecular weight impurities that were present in the 
protein sample after purification could have disrupted crystal packing. By switching from 
a nickel-affinity to cobalt-affinity column, binding specificity toward the His-tag was 
increased and those contaminants were removed. Second, the addition of the S-analog to 
the protein sample greatly enhanced crystallization. This indicates that the S-analog may 
be binding to the active site in a similar way as the native substrate, UDP-MurNAc- 
pentapeptide, which may lead to stabilizing certain conformations of E. coli MraY. Third, 
replacing all the detergent molecules with amphipathic polymers to stabilize the integral 
membrane protein MraY prevented aggregation of particles when imaged after negative 
staining. We collected and processed movies from a Talos Arctica operating at 200 keV, 
but the cryo-EM map we obtained was at a low resolution and we were unable to improve 
the resolution (data not shown here). 
 
 
Amphipols surrounding the protein complex do not add much size or have unique 
structural features and the overall complex size is challenging for the software to align 
and sort out particles in different orientations. This led to a switch to the nanodisc 
reconstitution system, which has potentially many benefits over the use of detergent and 
amphipols. One advantage of using nanodiscs over amphipols for the cryo-EM single 
particle analysis was its disc-shaped feature helped to pick out particles and easily 
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recognize their different orientations on the micrographs. Nevertheless, the cryo-EM 
 
data set collected from the fist nanodisc assembly with EYS21-L19F did not significantly 
improve the resolution. A possible explanation could be the flexible cytoplasmic side of 
the complex, where the soluble domain of protein E and SlyD interact. Determining a 
structure only of this region would help us to understand how protein E and SlyD interact 
and we could then, for example, introduce cross-links to stabilize this region. Increasing 
the number of particles and homogeneity could also improve the low-resolution EM 
maps. 
 
 
More efforts toward improving heterogeneity of the EYS21-L19F-nanodisc assembly 
sample and varying conditions for vitrification of cryo-EM grids are needed. The EYS21- 
L19F complex is estimated to be slightly larger than 100 kDa, from which long has been 
impossible to solve high-resolution cryo-EM structures. Recently, technical 
advancements with cryo-EM enabled obtaining cryo-EM maps for alcohol 
dehydrogenase (82 kDa) at 2.9 Å and methemoglobin (64 kDa) at 2.8 Å (Herzik, Wu & 
Lander, 2019). Along with traditional X-ray crystallography, cryo-EM is a powerful 
technique to solve structures of protein complexes and, for us, a high-resolution structure 
of EcMraY-protein E complex will contribute to development of novel antibacterial 
drugs in the time of antibiotic resistance crisis. 
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Figure 4.1. Purification of EYS21-L19F. A, an SDS-PAGE gel from a nickel-affinity column run with EYS21-L19F. 
The protein complex came off in the W4-E3 fractions. FT2, second flow-through; W1–2, wash with 20 mM imidazole 
and 10 mL each; W 3–4, wash with 20 mM EDTA and 10 mL each; E1–4, elute with 200 mM EDTA and 5 mL each; 
the first lane is Broad Range protein marker in kDa from Bio-Rad; B, purification of EYS21-L19F using an anion-
exchange column. Left, an anion-exchange (Uno Q6) chromatogram shows a single peak. Right, fractions 15–21 were 
run on an SDS-PAGE gel and there are high MW contaminants above the EcMraY bands; C, purification of EYS21-
L19F using a gel-filtration column. Left, a gel-filtration (Superdex 200 10/300) chromatogram shows a peak with a 
right shoulder. 
Right, fractions 9–13 were run on an SDS-PAGE gel and high MW contaminants are still there; D, in another 
purification batch, a gel-filtration column also gave a symmetrical peak without any shoulder. 
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Figure 4.2. Chemical structure of the S-analog of UDP-MurNAc-pentapeptide in a diastereomer mixture. The 
Kurosu laboratory synthesized this analog and purified using a HPLC HYPERSIL GOLDTM column with the solvent 
ratio of MeCN : 0.05 M NH4HCO3 (aq) = 5 : 95 and 2.0 mL/min flow rate. The product was detected at 254 nm. 
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Figure 4.3. Initial and optimized crystal hits of EYS21-L19F co-crystallized with the S-analog. 6 mg/ ml of 
EYS21-L19F and 100 µM analog formed crystals via the sitting-drop (A-C) or hanging-drop (D-G) vapor-diffusion 
method. A-C, three forms of crystals observed in the commercial screens (MemGold2 and Morpheus). D&E, 0.1 M 
MOPS pH 7.5, 0.2 M NaCl, and 38 % PEG 400 (MemGold2 E7). F&G, 0.05 M Tris pH 9.0, 0.3 M ammonium 
formate, and 33 % PEG 500 MME (MemGold2 F2). 
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Figure 4.4. 7.4 Å and 6.3 Å X-ray diffraction data collected on EYS21-L19F co-crystallized with the S-analog at 
the SSRL BL12-2. 6 mg/ml of EYS21-L19F and 100 µM analog formed crystals via the sitting-drop vapor-diffusion 
method. A, 0.01 M MES pH 6.5, 0.1 M sodium chloride, 0.15 M ammonium sulfate, and 19 % PEG 1000 (MemGold2 
B1). B, 0.1 M Carboxylic Acids, 0.1 M Buffer System 2, pH 7.5, and 50 % Precipitant Mix 3 (Morpheus G7). 
B A 
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Figure 4.5. Crystals of EYS21-L19F with the S-analog screened at the APS 23-ID-B. Two X-ray diffraction images 
were collected 90° apart from each crystal. The drops where individual crystals were harvested are shown in the top left 
corner of the first diffraction images. A, 0.1 M HEPES pH 7.5, 0.04 M MgCl2, and 32 % PEG 400 (MemGold2 F9). B, 
same drop from Fig. 4.3.G. C, same drop from Fig. 4.3.D. 
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Figure 4.6 Reconstitution of EYS21-L19F in amphipols and negative-stained images of the complex with the S- 
analog. A, a gel-filtration (Superdex 200 10/300) chromatogram and an SDS-PAGE gel with the gel-filtration 
fractions show the EYS21-L19F complex is stable in Apols. B&C, a negative-stained grid with 1.14 mg/ml protein 
and 210 µM analog was imaged using a Tecnai T12. The scale bar is 100 nm in B and 50 nm in C. 
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Figure 4.7. Detergent screening for extraction of EYS21-L19F. A, an SDS-PAGE gel of individual nickel-affinity 
columns runs with the EYS21-L19F complex extracted by six different detergents (DDM, DM, LDAO, β-OG, Fos- 
choline-12, and Cymal-5). Each detergent added is written on the top of the gels. Supernat, supernatant of the last 
ultracentrifuge run that contains solubilized protein; FT2, second flow-through; W1–2, 5 mL each; E1–E5, 1 mL each; 
E6, 5 mL. B, a gel-filtration (Superdex 200 10/300) chromatogram with overlaid peaks from DDM-, DM-, and Cymal-
5- containing running buffers. The black bar on the top indicates which area of the peak or fractions from the DDM run 
were used on a SDS-PAGE gel in C. D, a gel-filtration (Superdex 200 10/300) chromatogram with overlaid peaks from 
DM-, LDAO-, Fos-choline-12-, and β-OG-containing running buffers. 
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Figure 4.8. Optimized purification of EYS21-L19F. A, an SDS-PAGE gel from a cobalt-affinity column run with 
EYS21- L19F. The protein complex came off in the E1–3 fractions. FT2, second flow-through; W1–3, wash with 20 mM 
imidazole and 10 mL each; E1–4, elute with 200 mM imidazole and 5 mL each; the first lane is Broad Range protein 
marker in kDa from Bio-Rad; B, purification of EYS21-L19F using an anion-exchange column. Left, an anion-exchange 
(Uno Q6) chromatogram shows a single peak. Right, fractions 13–25 were run on an SDS-PAGE gel and the protein 
complex looks pure; C, purification of EYS21-L19F using a gel-filtration column. Left, a gel-filtration (Superdex 200 
10/300) chromatogram shows a peak preceding with two little shoulders. Right, fractions 9–13 were run on an SDS-PAGE 
gel and the protein complex is pure. 
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Figure 4.9. Purification of membrane scaffold proteins (MSPs) from E. coli cell debris. A, an SDS-PAGE gel of a 
nickel-affinity column from a 3L culture of MSP1D1 cell debris pellet. The fractions collected are enclosed in a red 
box. FT2, second flow-through; W1–6, please see the Materials and Methods section for the buffer composition, 10 mL 
each; E1–6, elute with 200 mM imidazole and 2 mL each; the first lane is Broad Range protein marker in kDa from 
Bio-Rad; B, a SDS-PAGE gel after TEV cleavage and a reverse nickel-affinity column. The fractions collected are 
enclosed in a red box. TEV protease, alone; before, the sample before TEV protease was added; 4 hr, 4 hours after the 
addition of TEV protease; FT2, second flow-through containing proteins without a His-tag; W1–4, wash with 10 mM 
imidazole, 5 mL each; E1–2, elute with 200 mM imidazole, 10 mL each; C&E, MSP1E3D1, and MSP2N2, 
respectively, in the same nickel-affinity purification conditions as in A; D&F, MSP1E3D1, and MSP2N2, respectively, 
in the same cleavage and reverse nickel-affinity purification as in B. 
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Figure 4.10. Reconstitution of EYS21-L19F into nanodiscs composed of MSP1E3D1 and DMPC. A, an SDS-
PAGE gel of a nickel-affinity column after the nanodisc assembly of EYS21-L19F in MSP1E3D1 and DMPC (DMPC : 
MSP1E3D1 : EYS21-L19F = 40 : 2 : 1). After the assembly, Bio-Beads (Bio-Rad) were added to remove any 
detergent. Beads were filtered out from the sample and it was incubated with Ni-NTA resin for a nickel-affinity column 
(fractions collected enclosed in red boxes). Then, beads were washed with MSP buffer and the remaining sample was 
incubated with Ni-NTA resin separately for another nickel-affinity column (fractions collected enclosed in blue boxes). 
FT2, second flow-through; W1–2, wash with 20 mM imidazole, E1–8, elute with 200 mM imidazole; B, a gel-filtration 
(Superdex 200 10/300) chromatogram showing a peak with two left shoulders. C, fractions 8–14 from the gel-filtration 
column were run on an SDS-PAGE gel. All three components of the protein complex as well as MSP1E3D1 appeared. 
Fractions in a red box were collected and concentrated. 
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Figure 4.11. Negative-stained images of the EYS21-L19F-nanodisc (DMPC, MSP1E3D1) assembly. The EYS21- 
L19F-nanodisc assembly was added to a 200-mesh copper grid covered with formvar/carbon film (#01801, Ted Pella, 
Inc.) followed by 2 % uranyl acetate. The scale bar is 100 nm in A and 50 nm in B. 
A B 
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Figure 4.12. Data analysis of cryo-EM images of the EYS21-L19F-nanodisc assembly using Relion-3. A, an 
example of a cryo-EM micrograph at a 19,965 Å defocus with particles manually picked (green circles) to make a 
template for 2D classification. B, 2D classification based on the template created from 1,089 particles in 89 selected 
micrograms. Six classes were selected (red boxes) for the next steps of data processing. C, based on the 2D average, 
particles from all of the micrograms were auto-picked (green circles). D, 3D classification from the auto-picked 
particles. 
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Figure 4.13. A 3D initial model of the EYS21-L19F-nanodisc assembly using Relion-3. This model was generated 
from the fourth class (24,323 particles) in Fig. 4.12.D and visualized with volume level 0.0741 in Chimera. A, a view 
from the periplasmic side. B, a view from the cytoplasmic side. C-E, side views. 
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Figure 4.14. Reconstitution of EYS21-L19F into nanodiscs composed of MSP1E3D1 and POPC/POPG. A, an 
SDS- PAGE gel of a nickel-affinity column after the nanodisc assembly of EYS21-L19F along with MSP1E3D1 and 
POPC/POPG (POPC/POPG : MSP1E3D1 : EYS21-L19F = 80 : 2 : 1). After the assembly, Bio-Beads (Bio-Rad) were 
added to remove any detergent. Beads were filtered out from the sample and it was incubated with Ni-NTA resin for a 
nickel-affinity column (fractions collected enclosed in red boxes). Then, beads were washed with MSP buffer and the 
remaining sample was incubated with Ni-NTA resin separately for another nickel-affinity column (fractions collected 
enclosed in blue boxes). FT2, second flow-through; W1–2, wash with 20 mM imidazole, E1–6, elute with 200 mM 
imidazole; B, a gel-filtration (Superdex 200 10/300) chromatogram showing a peak with a shoulder on the right side, 
followed by another small peak. C, fractions 8–12 from the gel-filtration column was run on an SDS-PAGE gel. All 
three components of the protein complex as well as MSP1E3D1 appeared. Fractions in a red box were collected and 
concentrated. 
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Figure 4.15. Negative-stained images of the EYS21-L19F-nanodisc (POPC/POPG, MSP1E3D1) assembly. The 
EYS21-L19F-nanodisc assembly was added to a 300-mesh copper grid (#2130C-XA, SPI Supplies) with a carbon layer, 
followed by 2 % uranyl acetate. The scale bar is 100 nm in A and 50 nm in B. 
A B 
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Figure 4.16. Another purification batch of MSP2N2 from E. coli cell debris. A, an SDS-PAGE gel from a nickel- 
affinity column for a 6L culture of MSP2N2 from cell debris pellet. The fractions collected are enclosed in a red box. 
FT2, second flow-through; W1–6, please see the Materials and Methods section for the buffer composition, 50 mL 
each; E1–6, elute with 200 mM imidazole and 10 mL each; the first lane is Broad Range protein marker in kDa from 
Bio-Rad; 
B, an SDS-PAGE gel after TEV cleavage and a reverse nickel-affinity column. The fraction collected is enclosed in a 
red box. before, the sample before TEV protease was added; 4 days, 4 days after the addition of TEV protease; FT2, 
second flow-through containing cleaved proteins; W1–2, wash with 20 mM imidazole, 10 mL each; E1–2, elute with 200 
mM imidazole, 10 mL each. C, left, a gel-filtration (Superdex 200 10/300) chromatogram with red bars indicating 
which area of the peaks corresponds to fractions 11, 12, and 13. The delay volume was 0.345 mL. Right, an SDS-
PAGE gel with fractions 9–15 from the gel-filtration chromatogram. Individual fractions of 11, 12, and 13 were 
proceeded to the nanodisc assembly step. 
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Figure 4.17. Negative-stained images of EYS21-L19F reconstituted in a variety of nanodiscs. The EYS21-L19F- 
nanodisc assembly was added to a 300-mesh copper grid (#2130C-XA, SPI Supplies) with a carbon layer, followed by 
2 % uranyl acetate. Nanodiscs were composed of: (A) MSP2N2 gel-filtration fraction 11 and POPC, (B) MSP2N2 gel- 
filtration fraction 11 and POPG, (C) MSP2N2 gel-filtration fraction 12 and POPC, (D) MSP2N2 gel-filtration fraction 
12 and POPG (Note that this image is hard to interpret. The grid used with this sample did not have enough area 
covered with the carbon layer.), (E) MSP2N2 gel-filtration fraction 13 and POPC, (F) MSP2N2 gel-filtration fraction 
13 and POPG. Scale bars are 50 nm long for all panels, except for D with 100 nm. 
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Figure 4.18. Overlay of gel-filtration chromatograms of EYS21-L19F purified at different NaCl concentrations. 
Protein sample ran with 0, 25, 50, 75 mM NaCl-containing buffer was from 3 L cell culture as opposed to the one with 
100 mM NaCl from 12 L cell culture. Superdex 200 10/300 was used. 
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Figure 4.19. The 4.20 Å X-ray diffraction data collected on EYS21-L19F co-crystallized with the S-analog at the 
SSRL BL12-2. The final concentration of the protein and the analog in the drop was 4 mg/ml and 500 µM, 
respectively. The crystallization condition was 0.1 M MES pH 6.6, 0.37 M potassium nitrate, and 21.5% PEG 400. A 
crystal was harvested from the drop that is shown in the top left corner of A. A and B are diffraction images that were 
acquired from exposing the crystal 90° apart. The resolution rings were drawn in using Adxv. Note. X-ray screening on 
May 3rd, 2019; the cassette number was 203; the port number was G6. 
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Table 4.1. Statistics of X-ray data collection of EYS21-L19F co-crystallized with the S-analog at 4.20 Å. Values in 
parenthesis are from the highest resolution shell. 
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MATERIALS AND METHODS 
 
Expression and purification of the EYS21-L19F complex 
 
Two plasmids that were used are pRSFDuet-E(ID21)(L19F)-His6-EcMraY (kanamycin
R) 
and pET22b-SlyD1-154 (carbenicillinR). They were co-transformed into the 
BL21(DE3)ΔSlyD competent cells. The colonies were scraped off into ~150 mL 
lysogeny broth  media with kanamycin (35 µg/ml) and carbenicillin (35 µg/ml) and 
shaken for a few hours at 37°C. Each 1 L 2x YT media (16 g/L tryptone, 
10 g/L yeast extract, and 5 g/L NaCl) was inoculated with ~10 mL of the starter culture 
and the cells grew at 37°C, shaking until optical density at 600 nm (OD600) reaches 0.6- 
0.7. The culture flasks were transferred to 22°C and induced with 1 mM isopropyl-β-D-1- 
thiogalactopyranoside (IPTG) when OD600 reaches 0.9–1.0 (to prevent lysis effect of E 
expression). The cells were grown overnight (16–20 hrs) and harvested using a JLA-8.1 
rotor at 4,000 rpm for 10 min. Cell pellet was resuspended in lysis buffer (20 mM Tris 
pH 7.5, 300 mM NaCl, 10 % glycerol, 5 mM βME, and protease inhibitors (e.g., PMSF, 
benzamidine)) and homogenized using a douncer. The cells were lysed by flowing 
through a microfluidizer four times. The lysate was spun down in a JLA-16.250 rotor at 
12,000 rpm for 30 min. Pellets were discarded and the supernatant was spun down in a 
Ti-45 rotor at 45,000 rpm for 30 min or 30,000 rpm for 1 hr. The membrane pellet was 
either stored at -80°C or resuspended in extraction buffer (10 mM HEPES pH 7.5, 300 
mM NaCl, 5 % glycerol, 5 mM βME, 10 mM imidazole, 1 % DM, and protease 
inhibitors). It was incubated for 2 hours at 4°C and spun down in a Ti-50.2 rotor at 
45,000 rpm for 30 min. The pellet was discarded and the supernatant was incubated with 
2.5 mL Ni-NTA resin (for 6L culture) overnight at 4°C. The sample was flown through a 
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gravity column twice and washed with 10 CV of a buffer (10 mM HEPES pH 7.5, 150 
mM NaCl, 5 % glycerol, 0.03 % DDM, 5 mM βME), containing 20 mM imidazole, 10 
CV of the same buffer with 20 mM EDTA, and eluted with the buffer containing 200 
mM EDTA. SDS-PAGE gel was used to validate the eluted sample. The eluate was 
dialyzed into Buffer A (10 mM HEPES pH 7.5, 100 mM NaCl, 5 % glycerol, 5 mM 
βME, 0.03 % DDM) overnight at 4°C and ran on an anion-exchange column (Uno Q6) in 
a gradient from 100 % Buffer A to 100 % Buffer B containing 500 mM NaCl. Purity of 
the sample was checked by SDS-PAGE and Coomassie staining and the fractions were 
run on a gel-filtration column (Superdex 200 16/600) with 10 mM HEPES pH 7.5, 100 
mM NaCl, 5 % glycerol, 5 mM βME, and 0.03% DDM. The purity and homogeneity 
were checked again by SDS-PAGE and the corresponding fractions were collected and 
used for structural studies right away or frozen at -80°C. 
 
 
Co-crystallization of EYS21-L19F with the S-analog. 
 
Initial crystallization screening started with adding 200 µM substrate analog to 12 mg/ml 
purified EYS21-L19F. The mixture was then filtered using an Amicon 0.22 m filter by 
spinning at 8,000 rpm for 5 min at 4C. For a standard sitting-drop vapor-diffusion 
method, the sample (0.2 L) was dispensed into individual wells on Swissci 96-well 
MRC plates (Molecular Dimensions), followed by well solution (0.2 L), which was 
drawn from a 50 L reservoir, using a Mosquito (TTP Labtech). Some of the commercial 
sparse matrices used were MemGold (Molecular Dimensions), MemGold2 (Molecular 
Dimensions), and Morpheus (Molecular Dimensions). 
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The crystallization conditions that gave initial crystal hits were categorized by the buffer, 
pH, salt, and a precipitant reagent. A grid screen was designed by varying pH and 
precipitant concentration around the condition in which crystals were observed, as salt 
concentration was kept constant. For setting up grid screens, I switched from the sitting- 
drop to the hanging-drop method and increased the drop size by adding 1 µL of protein 
sample that contains the substrate analog and 1 µL of the well solution. As optimization 
continued, the range of pH and precipitant concentration became finer and the volume 
ratio of protein sample to condition that go into drop varied along with the whole drop 
size. 
 
 
Initial crystallization screening for the LCP method started with mixing 12 mg/ml or 24 
mg/ml purified EYS21-L19F in addition to 200 µM substrate analog and monoolein 
(Sigma) at a 2:3 volume-to-volume ratio using a syringe lipid mixer. The protein/lipid 
mixture was dispensed on a glass plate using a Gryphon robot (Art Robbins Instruments). 
The volume ratios of the sample to crystallization condition used were 0.045 µL to 0.5 
µL, 0.045 µL to 1 µL, 0.2 µL to 0.8 µL, and 0.2 µL to 1 µL. One commercial sparse 
matrix, MemMeso (Molecular Dimensions), was used. The plates were stored at room 
temperature. 
 
 
Detergent screening for extraction of EYS21-L19F. 
 
The membrane pellet was prepared as above and resuspended into 10 mM HEPES pH 
7.5, 300 mM NaCl, 5 % glycerol, 5 mM βME, protease inhibitors, 10 mM imidazole, and 
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1 % of each of six detergents (DDM, DM, Cymal-5, β-OG, LDAO, and Fos-choline- 
12). After 2 hrs of rocking at 4°C, each of the samples were spun in a bench-top 
ultracentrifuge MLA-80 rotor at 30,000 rpm for 1 hr. Each supernatant was incubated 
with 250 µL of Ni-NTA resin rocking overnight at 4°C then passed through a gravity 
column. The samples were washed with 40 CV of 10 mM HEPES pH 7.5, 300 mM NaCl, 
5 % glycerol, 5 mM βME, 20 mM imidazole, and 2.5x CMC of a detergent of choice and 
eluted with 40 CV of the buffer with all the same components, except for 200 mM 
imidazole. Purity of the fractions were checked by SDS-PAGE and proceeded with a gel- 
filtration column (Superdex 200 10/300) with 10 mM HEPES pH 7.5, 150 mM NaCl, 
5 % glycerol, 5 mM βME, and 2.5x CMC of a detergent of choice. The fractions from 
peaks were chosen based on their purity by SDS-PAGE and concentrated using an 
Amicon 100 kDa MWCO concentrator. Varying amounts of white precipitates were 
observed for the DDM- and β-OG-solubilized sample during concentration. 
 
 
Reconstitution of the protein complex into a non-detergent polymer, amphipols 
 
Purified EYS21-L19F was incubated with amphipathic polymers (amphipols or Apols) in 
the ratio of 1: 2.9 (3.2 mg of protein and 9.6 mg of Apols) for 4 hours at 4°C. 69 mg of 
Bio-Beads (About 500 times excess amount of detergent DDM in the buffer) washed 
with 1 mL methanol twice and 1 mL milliQ water five times were added to the sample 
and incubated overnight at 4°C. An extra 100 µL of the buffer without DDM was added 
to 400 µL of the sample with Bio-Beads. Beads were removed by filter and the flow- 
through was injected into a gel-filtration column (Superdex 200 10/300) and run with the 
buffer without DDM (10 mM HEPES pH 7.5, 100 mM NaCl, 5% glycerol, 5 mM βME in 
122 
 
the presence or absence of 10 mM MgCl2). In the presence of MgCl2 in the running 
buffer, a shoulder appeared on the left side of the peak in the chromatogram (data not 
shown here). The fractions without MgCl2 (1.14 mg/ml) were incubated with 210 µM S- 
analog and used to prepare a negative-stained grid. 
 
 
Optimized of purification of the EYS21-L19F complex 
 
The overall purification process was similar to the one above with some modifications. 
Extraction was performed with 1 % DDM instead of DM after the detergent screening. 
Cobalt resin was used instead of Ni-NTA and the sample was washed with 30 CV of 10 
mM HEPES pH 7.5, 300 mM NaCl, 5 % glycerol, 5 mM βME, 0.03 % DDM, and 20 
mM imidazole, and eluted with the buffer containing 100 mM NaCl and 200 mM 
imidazole. 
 
 
Expression and purification of membrane scaffold proteins (MSPs) 
 
pMSP1D1 (Addgene plasmid # 20061), pMSP1E3D1 (Addgene plasmid # 20066), and 
pMSP2N2 (Addgene plasmid # 29520) were gifts from Stephen Sligar. All three plasmids 
had a His7 tag followed by a TEV cleavage site at the N-terminus of MSP in pET28a and 
they were transformed into Nico21(DE3) cells. The colonies were scraped off, added to 
150 mL of LB + kanamycin (35 µg/ml), and shaken at 37°C for a few hours. Culture 
flasks with 1 L 2xYT + kanamycin (35 µg/ml) were inoculated with about 10 mL of the 
starter culture. The cells were grown in a 225 rpm shaker at 37°C. When OD600 reached 
0.6–0.8, the cells were induced with 1 mM IPTG and grown for four more hours. 
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Cells were resuspended and homogenized in 50 mM Tris pH 8.0, and 500 mM NaCl, 
1 % Triton X-100, 1 mM EDTA, and 5 mM MgCl2 using a douncer. Two pills of 
protease inhibitor cocktail (cOmpleteTM, Roche) were added and stirred for 30 min at 
4°C. The cells were lysed as they ran through the microfluidizer for three passes at 15–18 
kpsi. The cell lysate was spun in an ultracentrifuge Ti-45 rotor at 20,000 rpm for 45 min. 
The cell debris pellet was scraped off and set aside for separate purification later. The 
supernatant was incubated with Ni-NTA resin (2–2.5 mL resin was used for proteins 
from 6 L culture.) for 2 hours, stirring at 4°C. The sample with Ni-NTA resin was run 
through a gravity column. The bound proteins were first washed with 10 CV of 1 % 
Triton X- 100-containing Buffer A (50 mM Tris pH 8.0 and 500 mM NaCl), followed by 
50 mM cholate-containing Buffer A, 20 mM imidazole-containing Buffer A, and 50 mM 
imidazole-containing Buffer A. The proteins were eluted with 10 mL of 200 mM 
imidazole-containing Buffer A and collected in 2mL fractions. Purity of all of the 
fractions from the nickel-affinity column was checked by SDS-PAGE and Coomassie 
stain. 
 
 
The cell debris pellet was resuspended and homogenized in 6 M Guanidine HCl, 50 mM 
Tris pH 8.0, and 500 mM NaCl using a douncer. This resuspension was spun in an 
ultracentrifuge Ti-45 rotor at 20,000 rpm for 45 min. The supernatant was incubated with 
Ni-NTA resin (2–2.5 mL resin was used for cell debris from 6L culture.) for 2 hours, 
rocking at 4°C. The sample was added to a gravity column. The bound denatured proteins 
were first washed with 10 CV of 6 M GuHCl-containing Buffer A (W1), followed by 10 
CV of Buffer A (W2), 1 % Triton X-100-containing Buffer A (W3), 50 mM cholate- 
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containing Buffer A (W4), Buffer A itself (W5), and 20 mM imidazole-containing 
Buffer A. The refolded proteins in the column was eluted with 10 mL of 200 mM 
imidazole-containing Buffer A and collected in 2 mL fractions. Purity of all of the 
fractions from the nickel-affinity column were checked by SDS-PAGE and Coomassie 
staining. 
 
 
The samples from soluble and insoluble portions of lysate were kept separated throughout 
the purification process. The fractions with proteins were dialyzed in 50 mM Tris pH 8.0, 
20 mM NaCl, and 0.5 mM EDTA overnight at 4°C to remove imidazole for subsequent 
TEV cleavage. Some of the dialyzed sample was saved for SDS-PAGE. 0.5–1 mg of TEV 
protease (expressed and purified in the lab) along with 1 mM DTT were added to each of 
the dialyzed samples. Some of the sample after 4 hours was saved and TEV cleavage 
continued overnight while rocking at 4°C. All DTT was dialyzed out overnight at 4°C in 
20 mM Tris pH 8.0 and 500 mM NaCl. Then, the sample was passed over nickel-affinity 
column to remove uncleaved sample and then with four 5-mL washes with 20 mM Tris 
pH 8.0, 100 mM NaCl, and 10 mM imidazole were collected followed by ten 2-mL 
elutions with 200 mM imidazole collected as fractions. After SDS-PAGE to ensure 
cleavage, cleaved MSPs were separated from TEV protease and other contaminants. 
Final dialysis was done with 20 mM Tris pH 7.5, 100 mM NaCl, and 0.5 mM EDTA. 
 
 
Reconstitution of the protein complex into nanodiscs. 
 
MSP buffer (20 mM Tris pH 7.5, 100 mM NaCl, 0.5 mM EDTA) and MSP buffer with 
100 mM cholate were first prepared. 35.1 mg of DMPC, 18.1 mg/17.2 mg of 
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DMPC/DMPG, 21.5 mg/19.3 mg of POPC/POPG were each solubilized in 1 mL of 
 
the cholate-containing buffer, making 50 mM lipid stocks. Then, all the components were 
mixed, so that the ratio of the protein complex : MSP : lipid becomes 1 : 2 : 80 (40 also 
tried) and the final concentration of cholate is 20 mM. Incubation of this mixture for an 
hour at room temperature for DMPC and DMPC/DMPG-containing assembly, whereas, 
with POPC/POPG, incubation was at 4°C. About 250 mg of Bio-Beads (Bio-Rad) were 
added into each nanodisc assembly sample and was incubated at the same temperature at 
least for an hour and up to four hours. Bio-Beads were filtered out and the sample was 
saved. The Bio-Beads were washed with extra MSP buffer and the washed sample was 
also saved. After incubation with 250 µL Ni-NTA resin overnight at 4°C, all of the 
samples were run on nickel-affinity columns, washed with 4 mL 20 mM imidazole- 
containing MSP buffer and eluted with 6 mL 200 mM imidazole-containing MSP buffer. 
After checking their purity with SDS-PAGE, certain fractions were selected for a gel- 
filtration column (Superdex 200 10/300), with 20 mM Tris pH 7.5, 100 mM NaCl, and 
0.5 mM EDTA. 
 
 
Preparation of negative-stained grids of the EYS21-L19F complex 
 
2 µL of purified EYS21-L19F (0.4 mg/ml) was pipetted onto either 300-mesh or 400- 
mesh copper grids that were carbon coated using a Cressington 208carbon and glow 
discharged using an Emitech K100X (15 mA, 1 min). After 50 sec, the excess protein 
sample on the grid was wicked away using Whatman No. 1 filter paper. Then, 2 µL of 2 
% uranyl acetate was pipetted on top of the grid and again, after 50 sec, the excess blotted 
away using the edge of the filter paper. 
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Imaging a negative-stained grid of the EYS21-L19F complex using a 120 keV 
transmission electron microscope (TEM) 
A Tecnai T12 equipped with an electron gun, LaB6, and Gatan Ultrascan 2k x 2k CCD 
was used to image the negative-stained grid of the protein complex. The SA range 
magnification, 26,500- 52,000x, was used to visualize particles. 
 
 
Cryo-EM grid preparation, data acquisition, and image processing 
 
A copper Quantifoil R2/2 grid was glow discharged at 15 mA for 1 min using Pelco 
easiGlow. Using a FEI Vitrobot (Mark v4), 3 µL of the protein sample (0.4 mg/ml) 
reconstituted in nanodisc (DMPC/MSP1E3D1) was applied to the grid and blotted with 
Whatman No. 1 filter paper with the blot force -5 for 2 sec at 4°C and with 100 % 
humidity. Immediately after blotting, the grid was plunge frozen in liquid ethane cooled 
by liquid nitrogen. The grid was first screened using Talos Arctica equipped with a FEG 
operating at 200 keV and the 4k x 4k FEI Falcon III direct electron detector. 
 
 
Movies were collected using a Titan Krios that operates at 300 keV, equipped with the 
Gatan K3 4k x 4k direct electron detector in counting mode (0.834 Å/pixel) at a 
magnification of 165,000x using a defocus range of -0.8 to -2.7 µm. Movies were 
collected over an 8 second exposure (40 frames) with an exposure rate of 5.9 e-/pixel/sec, 
resulting in total exposure of 1.7 e-/Å2/frame. All image processing was done using 
Relion-3 (Scheres, 2012; Zivanov et al., 2018). Motion correction was performed using 
the MotionCor2 frame alignment program (Chen et al., 2013). CTF determination was 
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performed using CTFFIND4 (Cardone, Heymann & Steven, 2013). A total of 1,089 
particles were manually picked for 2D classification. Six 2D classes were selected for a 
template for automatic particle picking. Then, all the images were manually inspected to 
remove selection on things that were not particles. Using a 2D class average, 3D 
classification was performed, and 3D initial models were obtained from 23,121 ~ 45,285 
particles/class. 
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C h a p t e r 5 
 
 
Insight into the catalytic mechanism of the bacterial phosphotransferase MraY 
 
 
ABSTRACT 
 
The peptidoglycan is a protective layer conserved in nearly all bacteria, but it is not present 
in eukaryotic cells. Enzymes involved in the biosynthesis pathway of peptidoglycan have 
been attractive targets for designing antibacterial agents for decades. One of the most 
promising targets (Silver, 2013) is the first membrane-bound enzyme in the pathway, called 
MraY. Despite structural and biochemical information available for MraY, more 
investigation to elucidate the catalytic mechanism and binding modes of native substrates 
awaits. In this study, a dUMP exchange reaction supports the model that MraY from 
Hydrogenivirga sp. undergoes a one-step mechanism, in which both of the substrates, 
UDP-MurNAc-pentapeptide and C55-P, are required to form a non-covalent ternary 
complex to produce Lipid I and UMP. Based on the result of fluorescence-based 
continuous activity assay of MraY, we suggest MraY undergoes, more specifically, an 
ordered Bi–Bi mechanism. Furthermore, we performed extensive mutagenesis on invariant 
aspartate, lysine, and histidine residues located in the putative active site of MraY. The 
comparison of activity of mutants to their binding to UDP-MurNAc-pentapeptide suggests 
that D117 is important in binding and D196 is critical for catalysis. Dependence of MraY 
activity on the concentration of Mg2+ and pH were also investigated. In total, this work 
provides important insight into the mechanism of an important antibiotic target. 
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INTRODUCTION 
 
The majority of bacteria contain the peptidoglycan (PG) layer as a major constituent of 
their cell wall, which protects the cells from internal turgor pressure and helps them to 
maintain their cell shape (Lovering et al., 2012). In addition, a functional peptidoglycan 
layer is required for effective cell division (Vollmer et al., 2008). Because the 
peptidoglycan layer is unique to bacteria, many enzymes involved in this pathway have 
been the site of action of antibacterial agents, including clinically important β-lactam 
antibiotics (Bugg, 1999). All of the enzymes in the peptidoglycan biosynthesis pathway 
have been structurally characterized in one species or another. However, mechanistic 
understanding of some of them lags behind largely due to the absence of substrate(s)- 
bound structures. One of them is MraY, the first integral membrane protein that catalyzes 
the reaction of making the first lipid-bound building block (Lipid I) in the PG 
biosynthesis pathway. Apo and inhibitor-bound MraY crystal structures are currently 
available (Chung et al., 2016, 2013; Hakulinen et al., 2017), but they cannot clearly 
resolve the binding mode of the two substrates, UDP-MurNAc-pentapeptide and 
undecaprenyl phosphate (C55-P). 
 
 
Decades of efforts by many groups were devoted to elucidating the mechanism of MraY 
using biochemical tools. In 1969, Heydanek et al. first proposed a two-step mechanism of 
MraY, which involves forming a covalent MurNAc-pentapeptide-phosphoenzyme 
intermediate and the subsequent release of the enzyme by a nucleophilic attack of C55-P 
(Heydanek, Struve & Neuhaus, 1969). In 2004, Bouhss et al. first reported that MraY can 
be purified to homogeneity and its catalytic reaction requires Mg2+ (Bouhss, 
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Crouvoisier, Blanot & Mengin-Lecreulx, 2004). With pure MraY in hand, Al- 
 
Dabbagh et al. proposed an alternative one-step mechanism, which requires the formation 
of a ternary complex of the enzyme and two substrates for the reaction to occur (Al- 
Dabbagh et al., 2008). More recently, exchange reaction results of MraY from Bacillus 
subtilis using isotopes were in agreement with the one-step mechanism (Al-Dabbagh et 
al., 2016; Yao Liu et al., 2016). 
 
 
Here, we propose MraY from Hydrogenivirga sp. also undergoes the one-step 
mechanism based on the evidence from a direct exchange reaction. We fit a continuous 
activity assay result into bisubstrate reaction models and the double-reciprocal plot 
indicates an ordered bisubstrate rather than ping pong bisubstrate mechanism. In 
addition, we discuss, via extensive mutagenesis and activity studies, which of the 
conserved residues in the active site may have potential roles in catalysis. Lastly, residues 
critical to substrate binding were determined by fluorescence anisotropy. 
132 
 
RESULTS 
 
dUMP exchange reaction indicates both substrates are required concomitantly for the MraY 
catalytic reaction 
As depicted in Figure 5.1.A, both one-step and two-step mechanisms have been proposed 
for the catalytic reaction of MraY. In a one-step mechanism, the MraY enzyme along with 
its two substrates, UDP-MurNAc-pentapeptide and C55-P, are all required to form a ternary 
complex for catalysis, resulting in the formation of the two products, Lipid I and UMP. More 
specifically, it is currently believed that an invariant active site residue on MraY deprotonates 
a hydroxyl group of the phosphate group on C55-P to make an oxyanion, which acts as a 
nucleophile to attack the β-phosphate group of UDP-MurNAc-pentapeptide to form both of 
the products. On the other hand, in a two-step mechanism, UDP-MurNAc-pentapeptide is 
first needed to form a covalent intermediate with the enzyme and forms UMP as the first 
product. This is followed by the nucleophilic attack of an oxyanion of C55-P on the 
intermediate to produce Lipid I. 
 
 
In order to prove which catalytic path MraY takes, we designed and performed an experiment 
that would prove the substrate requirements for the reaction. We first heterologously 
overexpressed MraY from a thermophilic species, Hydrogenivirga sp. in Escherichia coli 
and purified it with extensive washing steps in a cation column to completely remove 
endogenous C55-P. Purified HyMraY was then incubated with UDP-MurNAc-pentapeptide, 
dUMP, and MgCl2 in the presence and absence of C55-P at room temperature. The reactions 
were stopped by boiling, butanol was added to extract the hydrophobic substrate/product, 
and the aqueous layer was isolated and subject for LC-MS analysis. The rationale behind this 
133 
 
experiment is that when a reaction has all substrate(s) required for catalysis, the reaction 
will reach equilibrium, with the reverse reaction incorporating dUMP into UDP-MurNAc- 
pentapeptide. In other words, the UMP leaving group from the forward reaction is replaced 
by dUMP in the reverse reaction to generate dUDP-MurNAc-pentapeptide. We first 
confirmed that dUMP acts as a product inhibitor to a similar extent as UMP supporting that 
it behaves similarly in the reaction (Fig. 5.1.B). 
 
 
At equilibrium, in the presence of excess dUMP, LC-MS analysis of the aqueous layer 
revealed that both substrates were required for dUMP incorporation into dUDP-MurNAc- 
pentapeptide (Fig. 5.1.C). In the first four reactions Figure 5.1.C, background incorporation 
was seen suggesting contaminating C55-P; therefore, it was critical to remove endogenous 
C55-P by extensive washing (reactions boxed in yellow). 
 
 
HyMraY uses an ordered Bi–Bi mechanism. 
 
In order to measure the activity of HyMraY, UDP-MurNAc-pentapeptide was first treated 
with dansyl-chloride to attach a dansyl group (DNS) to N of m-DAP, the third amino acid 
of the pentapeptide which had been shown to not affect catalysis (Stachyra, Dini, Ferrari, 
Bouhss, Van Heijenoort, et al., 2004). Each reaction mixture contained HyMraY, UDP- 
MurNAc-pentapeptide-DNS, C55-P, and MgCl2 in the buffer with DM. Reactions were 
incubated at 37°C for 30 min, diluted, and the fluorescence was measured across 380–700 
nm (Fig. 5.2.A left). Alternatively, butanol (BuOH) was incubated with the reaction sample 
and the BuOH layer was pipetted from the aqueous layer to obtain only the hydrophobic 
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product (Fig. 5.2.A right). In this reaction, as seen previously a simplified substrate C20- 
P could be substituted for C55-P (Fig. 5.2.A) (Y. Zheng, Struck & Young, 2009). 
 
 
A continuous fluorescence-based assay was developed to measure the initial rate of reaction 
in the linear region of the Michaelis-Menten curve. The reaction mixture with purified 
HyMraY, dansylated UDP-MurNAc-pentapeptide, and C55-P was initiated with the 
addition of MgCl2 in a plate reader and fluorescence from dansylated Lipid I was monitored 
for the first eight min. For one set of experiments, while the concentration of UDP- 
MurNAc-pentapeptide-DNS varied, the concentration of C55-P was kept constant to be 7.5 
µM. Two more sets of experiments were performed for 20 µM and 50 µM C55-P. The 
concentrations of UDP-MurNAc-pentapeptide-DNS and its corresponding initial velocity 
(v0) were subsequently used to draw a double-reciprocal plot with 1/v0 vs. 1/[UDP-MurNAc- 
pentapeptide-DNS]. In the double-reciprocal plot, there is a crossover point in the second 
quadrant met by three lines, each formed when concentration of C55-P was kept constant 
(Fig. 5.2.B). According to Leskovac, this indicates the enzyme going through ordered Bi–Bi 
mechanism (Leskovac, 2003) rather than ping pong Bi–Bi mechanism. 
 
 
Mutagenesis studies of HyMraY to identify residues critical for catalysis. 
 
Al-Dabbagh et al. first proposed one-step mechanism for MraY from B. subtilis along with 
the invariant D98 playing a role in deprotonating the phosphate group of C55-P (Al-Dabbagh 
et al., 2008). Based on the in vivo complementation assay, they showed 14 mutants including 
D98N are essential for activity (Al-Dabbagh et al., 2008). To confirm this analysis, we 
generated mutants of HyMraY that correspond to the residue of D98 (B. subtilis) in HyMraY 
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(D117) to either alanine (A), asparagine (N), or glutamate (E) (Fig. 5.3.AB). The level of 
expression and protein yield of the mutants after purification was similar to those of the wild 
type. All of the mutants D117A, D117N, and D117E were then subject to the activity assay 
using the quenched fluorescence-based method (Fig. 5.2.A). All showed significant to 
complete loss of activity. Compared to the control without Mg2+, D117E showed some 
minimal activity (Fig. 5.3.B). This indicates that a longer carboxylic acid side chain could 
support catalysis, although significantly less efficiently. 
 
 
In addition to D117, four other invariant aspartate residues located in the putative active site 
were mutated (Fig. 5.3.A). All four residues (D118, D193, D196, and D265) were each 
mutated to either asparagine or glutamate and they expressed and purified similarly to wild 
type. D118N had no activity, but D118E retained more than half of the wild-type activity 
(Fig. 5.3.B). This is similar to the D117 mutants, although the activity was less sensitive to 
the long Glu side chain. Neither the D265N or D265E mutations showed significant loss of 
activity (Fig. 5.3.B), suggesting that D265 is not as critical as D117 and D118. Amer and 
Valvano reported a potential catalytic role of the corresponding residues of D117 and D118 
in HyMraY (D90 and D91) and another invariant D156 in EcWecA, a similar 
phosphotransferase to MraY, due to the failure in functional complementation in vivo and a 
large reduction in transferase activity in vitro (Amer & Valvano, 2002). Based on their 
multiple sequence alignment, D156 as well as D159 of EcWecA are part of the conserved 
region, 150-NAFNMVDGIDGL-161, across WecA homologs (Amer & Valvano, 2002). 
The corresponding aspartate residues in HyMraY are D193 and D196, which are completely 
conserved across MraY homologs, were again mutated to Asn or Glu (Fig. 5.6). For the case 
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of the D193 mutants, while the longer side chain of D193E lost activity, the amide side 
chain of D193N retained some activity (Fig. 5.3.C). Both D196N and D196E were 
completely dead (Fig. 5.3.C), and thus D196 is critical in activity of HyMraY. 
 
 
We further mutated K121 and K133 that are highly conserved across MraY orthologs and 
the side chains are facing toward the putative active site in the published AaMraY (same 
numbering as HyMraY) and CbMraY (K97 and K111) structures. The initial motivation to 
investigate functional roles of these lysine residues was because Schaefer et al. proposed 
conserved arginine residues play a role as general bases to deprotonate a phosphate group of 
the lipid substrate in the LCP complex, which is a wall teichoic acid precursor transferase 
(Schaefer, Owens, Kahne & Walker, 2018). Also, lysine residues were proposed to have a 
role in positioning the phosphate group of C55-P for its nucleophilic attack on UDP-GlcNAc 
in a human ortholog of MraY, DPAGT1, involved in the N-linked glycosylation pathway 
(Dong et al., 2018). Both K121A and K133A retained more than half of the wild-type 
activity, suggesting they are not catalytically essential (Fig. 5.3.D). 
 
 
Among the members of N-acetylhexosamine-1-phosphate transferase superfamily, MraY 
sequences uniquely have a conserved 13-mer, 320-MAPIHHHFELKGW-332, in the loop 
between TM9 and TM10 (Anderson, Eveland & Price, 2000). Since the members are 
specific to a variety of soluble substrate with a nucleotide donor, this sequence analysis led 
us to consider that this loop is potentially involved in soluble substrate recognition. We 
mutated H324, H325, and H326 to alanine. We found that the activity of H326A was 
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comparable to that of the wild type and H325A retained about half of the wild-type 
activity, whereas H324A resulted in a loss of activity (Fig. 5.3.EF). 
 
 
The activity of HyMraY is dependent on Mg2+ concentration and pH 
 
The effects of magnesium and pH on the activity of HyMraY and mutants were tested. Al- 
Dabbagh et al. reported the activity for the BsMraY wild type was optimal at 30–60 mM 
Mg2+, while activity was abolished at Mg2+ concentrations higher than 100 mM (Al- 
Dabbagh et al., 2008). They suggested some mutants of BsMraY (H45R, D174N and 
D177N) became active at 250 mM Mg2+, suggesting these residues are possibly involved in 
the binding of the metal ion. Here we assayed the wild type, D193N, D193E, D196N, and 
D196E of HyMraY in the presence of increasing concentrations of MgCl2 (0–250 mM) to 
investigate whether the lack of activity can be attributed to impaired Mg2+ binding. However, 
no activity could be recovered for D193E, D196N, or D196E mutants and the wild-type 
HyMraY activity was optimal at 150 mM Mg2+ (Fig. 5.4.A). Furthermore, the effect of pH 
was examined in the range 6.5–9.8 for the wild type, D117N, and D118N. Al-Dabbagh et al. 
reported D98N had a distinct pH profile compared to the wild type, recovering maximal 
activity at pH 9.0–9.4 (Al-Dabbagh et al., 2008). Based on this result, the authors proposed 
that D98 is involved in deprotonating C55-P, which is essential for activity and a one-step 
mechanism. However, no recovery in enzymatic activity was observed for the mutants in our 
assay (Fig. 5.4.B). 
 
 
Altered activity of HyMraY mutants is correlated with change in binding of UDP-MurNAc- 
pentapeptide 
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To measure substrate binding to HyMraY and various mutants, a fluorescence anisotropy 
assay was used taking advantage of changes in the rotational tumbling of a fluorescently 
labeled UDP-MurNAc-pentapeptide. Binding of UDP-MurNAc-pentapeptide-DNS to MraY 
leads to a decrease in rotational rate and an increase in fluorescence anisotropy. The 
fluorescent tag of substrate UDP-MurNAc-pentapeptide-DNS does not interfere with 
enzymatic reaction as previously demonstrated (Stachyra, Dini, Ferrari, Bouhss, van 
Heijenoort, et al., 2004). Additionally, changes in fluorescence anisotropy have been 
successfully applied to other membrane proteins (Gerber et al., 2013; Rinken, Lavogina & 
Kopanchuk, 2018). 
 
 
The fluorescence anisotropy assay yielded a dissociation constant Kd of 5.2 M for UDP- 
MurNAc-pentapeptide-DNS binding to HyMraY that was dependent on Mg2+ (Fig. 5.5.A) 
and was lost in the presence EDTA after reaching saturation (data not shown). No significant 
change in anisotropy is observed in a control experiment with an unrelated membrane protein 
(TatC) suggesting that substrate UDP-MurNAc-pentapeptide-DNS binds to HyMraY 
specifically (data not shown). The results support that C55-P is not required for binding of 
UDP-MurNAc-pentapeptide-DNS into the active site of HyMraY. 
 
 
Detergent micelles could complicate anisotropy measurements; therefore, to prevent this 
HyMraY and the variants were exchanged into amphipathic polymers (amphipols or Apols). 
This allows for solubilization of the protein in the absence of detergents (Tribet et al., 1996). 
When assayed using the water-soluble lipid-substrate analog, neryl phosphate (C10-P), 
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HyMraY in amphipols remained active at levels comparable to HyMraY in detergent 
(data not shown). This validates further study of HyMraY in amphipols. 
 
 
Anisotropy experiments were performed with all mutants described above to determine the 
effect on binding of dansylated-UDP-MurNAc-pentapeptide. As before, HyMraY mutants 
in amphipols were titrated into a solution of UDP-MurNAc-pentapeptide-DNS and 
fluorescence anisotropy was measured at 550 nm emission. The results are generally in 
agreement to enzymatic activity of the mutants (Fig. 5.5). The H326A mutant, which is 
enzymatically equipotent to the wild type, also exhibits equivalent binding of UDP- 
MurNAc-pentapeptide-DNS (Fig. 5.5.B), so, despite its conservation H326 does not play a 
direct role in substrate binding or catalysis. For H325A, a slight increase in anisotropy 
correlating with protein concentration was observed (Fig. 5.5.B) in agreement with the 
reduced enzymatic activity of this mutant. H324A showed no binding of UDP-MurNAc- 
pentapeptide-DNS (Fig. 5.5.B). It is likely that H324A plays a direct role in substrate 
recognition. The enzymatically inactive mutants D117A, D118A and D265A also exhibit an 
anisotropy increase at higher protein concentrations indicating that UDP-MurNAc- 
pentapeptide-DNS weakly binds (Fig. 5.5.B). 
 
 
For the rest of the mutants designed to remove charge of the residue with minimal steric 
change, varying results were seen. The D265N mutation binding is not dramatically reduced 
consistent with its retention of half wild-type activity (Fig. 5.5.C). Both D118N and D196N 
resulted in a loss of substrate binding in agreement with the loss of enzymatic activity (Fig. 
5.5.C). Both D193N and D117N had a similar reduction in binding. For D193N, this was 
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consistent with the retention of some activity, while for D117N despite the ability to bind 
substrate the mutation led to a complete loss of activity (Fig. 5.5.C). All of the conserved 
aspartate residues were mutated to glutamate and binding to the dansylated substrate was 
measured. For all of the mutants (D117E, D118E, D193E, D196E, D265E), the level of 
activity and the degree of binding were well correlated (Fig. 5.5.D) suggesting that a 
component of the reduction in activity caused by introduction of a larger side chain is due to 
weaker binding of UDP-MurNAc-pentapeptide-DNS to the active site in HyMraY. 
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DISCUSSION 
 
In order to determine whether MraY undergoes a one-step or two-step mechanism, we 
designed and performed dUMP exchange reaction. In our first trial, in addition to Rx 2 
and Rx 4, residual amount of UDP-MurNAc-pentapeptide with dUMP incorporated was 
detected from Rx 1 and Rx 3 (Fig. 5.1.C). We speculated that these signals could be 
coming from endogenous C55-P that was extracted along with MraY from the E. coli 
membrane and stayed in detergent micelles during the process of purification. As 
predicted, an LC-MS analysis of purified protein sample detected some C55-P present. 
This likely was a problem for previous experiments that had resulted in different 
outcomes. For subsequent expression, MraY was extensively washed to ensure removal 
of all C55-P, confirmed by LC-MS. The dUMP exchange reaction with this sample 
showed that dUMP incorporation was only detected in Rx 6 and Rx 8 (Fig. 5.1.C) when 
both substrates of MraY are present. Thus, HyMraY catalyzes its reaction via a one-step 
mechanism in agreement with results seen for BsMraY (Al-Dabbagh et al., 2016; Yao 
Liu et al., 2016). 
 
 
An enzymatic reaction that involves two substrates and two products in steady state can 
be first tested whether it undergoes ordered Bi–Bi or ping pong Bi–Bi mechanisms. 
Based on our double-reciprocal plot revealing an intersection point of three straight lines 
in the second quadrant (Fig. 5.2.B), we suggest ordered Bi–Bi mechanism and exclude 
ping pong Bi–Bi mechanism since we expect to see parallel lines for the latter. However, 
more data analysis is required to distinguish ordered from random Bi–Bi mechanism. 
Also, it 
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is critical to perform product inhibition experiments in order to confirm the mechanism 
(Leskovac, 2003). 
 
 
We performed an extensive mutagenesis screening for invariant aspartate, lysine, and 
histidine residues that are positioned in the putative active site facing toward the cytoplasm. 
In contrast to previous mutagenesis studies, we established baselines by measuring activity 
of mutants in the absence of Mg2+. Both mutations of D196 to asparagine and glutamate 
abolished activity (Fig. 5.3.C). Interestingly, the side chain of D196 faces away from the 
cavity of MraY in an apo MraY structure (PDB ID: 4J72), but it is positioned into the 
cavity in both of the inhibitor-bound MraY structures (PDB ID: 5CKR, 5JNQ). This 
suggests D196 can move to the position to catalytically act on the substrates once they are 
bound. Other mutants worth mentioning are the D117 and D118 mutants. While activity of 
both D117N and D118N was completely lost, D117E and D118E retained some of their 
activity. This means having a carboxylic acid in the side chain, even though there is one 
extra carbon, is critical for activity. Based on these findings, we postulate the carboxylic 
acid on D117 and D118 may be coordinating Mg2+ that is required for catalysis. 
 
In order to identify residues that are important in substrate binding, the same HyMraY 
mutants used to measure activity were subject to binding assays measured by 
fluorescence anisotropy. Although lipid substrate, C55-P, was not required to monitor 
UDP-MurNAc-pentapeptide binding to the enzyme, Mg2+ was required for its binding 
(Fig. 5.5.A). In general, we observed similar effects of mutations on binding as on 
activity. For example, D196N and D196E displayed no activity and no binding. However, 
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the D117 mutants (D117A, D117N) that were inactive (Fig. 5.3.B) retained weak 
binding (Fig. 5.5.BC) to UDP-MurNAc-pentapeptide. This suggests the importance of 
D117 in binding of the substrate in the active site. Additional polarization experiments at 
higher protein concentrations should be conducted to establish whether maximal anisotropy 
of the wild type could eventually be achieved with mutants and Kd correctly calculated. 
 
 
In order to confirm how catalysis is performed by MraY, determining a structure of 
MraY in complex with two substrates is crucial. Molecular details of the active site of 
MraY will be compared to the biochemical data and confirm which residues are critical in 
catalysis and substrate binding. Nonetheless, our dUMP exchange reaction results and the 
double-reciprocal plot provide new mechanistic insights that MraY from Gram-negative 
bacteria undergoes a one-step mechanism and, more specifically, ordered Bi–Bi 
mechanism. In addition, extensive mutagenesis studies were performed on activity and 
substrate binding in parallel and revealed some residues that need attention for structural 
studies and further designing of antibiotics. 
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Figure 5.1. Mechanistic scheme and dUMP exchange reaction. A, Two proposed mechanisms of MraY. Two-step 
mechanism requires UDP-MurNAc-pentapeptide first to form a covalent MurNAc-pentapeptide-phosphoenzyme 
intermediate and releases UMP, followed by a nucleophilic attack by C55-P for Lipid I formation. One-step mechanism 
requires both of the substrates for the reaction to go forward and produce both UMP and Lipid I. Since the catalytic 
reaction by MraY is reversible, depending on at which point of reaction we added dUMP, we could monitor incorporation 
of dUMP back to UDP-MurNAc-pentapeptide, which is shown in red. B, Inhibition of HyMraY by UMP and dUMP. C, 
LC-MS results of dUMP exchange reaction. The first four reactions (Rx 1–4) with different compositions listed had deoxy 
UDP-MurNAc-pentapeptide detected everywhere (inset). After more stringent purification of HyMraY, four reactions 
were repeated (Rx 5–8) with new dUMP concentration (10 mM) in addition to a negative control without MgCl2 added 
(shaded in yellow). The LC-MS result for Rx 5–8 shows that only in the presence of both of the substrates, deoxy UDP- 
MurNAc-pentapeptide was detected. Park: UDP-MurNAc-pentapeptide is also called Park’s nucleotide; dPark: deoxy 
Park’s nucleotide. Lada Klaić, Ph.D. designed and performed experiments. 
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Figure 5.2. Continuous fluorescence activity assay of HyMraY. A left, An example of a fluorescence trace from 
reaction mixture containing purified HyMraY and two substrates (either native C55-P or C20-P and dansylated UDP- 
MurNAc-pentapeptide). As compared to traces from inactivated HyMraY or the absence of lipid substrate, the peaks 
from reaction with lipid substrates shifted from 550 nm to 532 nm. A right, The same reaction as in A left, but only the 
butanol layer was subject to fluorescence measurement. Product (dansylated Lipid I) was extracted into this organic 
layer, whereas unreacted soluble UDP-MurNAc-pentapeptide-DNS stayed in the aqueous layer. All of the samples 
mentioned above were excited at 340 nm and scanned from 380 to 780 nm. B, A double-reciprocal plot of HyMraY. 
Using the method shown in A right, activity of reactions in a range of UDP-MurNAc-pentapeptide-DNS concentrations 
was measured and reaction rate was determined for each concentration. Repeat this using three different concentrations 
of C55-P. Then, a double-reciprocal plot was drawn and it reveals one intersection point of three lines in the second 
quadrant. Lada Klaić, Ph.D. designed and performed experiments. 
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Figure 5.3. Mutagenesis and fluorescence activity assay of HyMraY. A, Chain A of MraY from A. aeolicus (PDB ID: 
4J72) was drawn in cartoon representation and colored in rainbow with the N-terminus in blue and C-terminus in red. 
The cytoplasm and periplasm were indicated in the bottom and top of the structure, respectively. The inset has the 
magnified view of the cavity with conserved aspartate and lysine residues that were mutated in this study. The side chains 
of those residues are shown in stick representation and the Mg2+ ion in purple sphere. PyMOL was used to visualize the 
AaMraY structure. B, Fluorescence activity assay was performed for the wild-type and mutants of D117, D118, and 
D265. Activity of the wild type and all of the mutants were measured in triplicates, except for D117A, D118A, and 
D265A measured only once. B1, Fluorescence measurement of product was performed for the wild type, D117N, and 
D118N in the absence and presence of MgCl2 to confirm the baseline. Activity of all of the enzymes here was measured 
in triplicates. B2, Fluorescence was measured for activity of the wild type, D117E, D118E, and D265E in the absence 
and presence of MgCl2. Activity of all the HyMraY enzymes here was measured in triplicates. C, Fluorescence was 
measured for activity of the wild type, D193N, D193E, D196N, and D196E with or without MgCl2. Activity of the wild 
type and all of the mutants here were measured in duplicates. D, Activity of K121A and K133A was measured along 
with the wild type. Activity of the wild type and two mutants were measured in triplicates. E, Same cartoon representation 
of AaMraY (PDB ID: 4J72) as in A, but tilted to show the HHH motif on loop E. F, Fluorescence of dansyl group on 
product was measured for the wild type, H324A, H325A, and H326A. Activity of the wild type and all three mutants 
were measured in duplicates. The error bars represent standard deviation in all panels above. Lada Klaić, Ph.D. designed 
and performed experiments. 
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Figure 5.4. Mg2+ and pH dependence of HyMraY activity. A, Activity of the wild type and four mutants of HyMraY 
(D193N, D193E, D196N, D196E) was monitored in the range of 0–250 mM MgCl2. While the wild-type activity was 
measured once, activity of all the mutants was measured in duplicates. The error bars with standard deviation were 
shown only for D193N because the other three mutants are inactive. B, Activity of the wild type and two mutants of 
HyMraY (D117N, D118N) was measured in the range of pH 6.5–9.8. Lada Klaić, Ph.D. designed and performed 
experiments. 
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Figure 5.5. Florescence anisotropy assay for measuring binding of UDP-MurNAc-pentapeptide-DNS to 
HyMraY. A, Fluorescence anisotropy measurement was performed for the wild-type HyMraY with UDP-MurNAc- 
pentapeptide-DNS in the presence (red circle) and absence (black square) of Mg2+. B, Anisotropy was measured for the 
alanine mutants of D117, D118, D265, D324, D325, and D326. C, Anisotropy was measured for the asparagine 
mutants of D117, D118, D193, D196, and D265. D, Anisotropy was measured for the glutamate mutants of D117, 
D118, D193, D196, and D265. All of the data points were moved to start from zero anisotropy and fitted using one site 
specific binding in Prism. Lada Klaić, Ph.D. designed and performed experiments. 
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Figure 5.6. Multiple sequence alignment of orthologs of MraY. Sequences of MraY orthologs were from 
Hydrogenivirga sp., Aquifex aeolicus, Escherichia coli, Bacillus subtilis, Clostridium bolteae, and Mycobacterium 
tuberculosis. Multiple sequence alignment was performed using ClustalX. Each one-letter code of amino acids 
background colors based on the chemical properties of side chains. The background colors are following: blue 
represents Ala (A), Ile (I), Leu (L), Met (M), Phe (F), Trp (W), Val (V), Cys (C) (>60%); red represents Lys (K), Arg 
(R); magenta represents Glu (E), Asp (D); green represents Asn (N), Gln (Q), Ser (S), Thr (T); pink represents Cys (C) 
(>85%); orange represents Gly (G); yellow represents Pro (P); cyan represents His (H), Tyr (Y). The columns with 
asterisks on the top indicate full conservation. The HyMraY invariant residues that were subject to mutagenesis studies 
have the asterisks colored red. The residue numbering on the bottom of the alignment is from HyMraY. 
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MATERIALS AND METHODS 
 
Expression and purification of HyMraY 
 
The wild-type and mutant constructs of HyMraY with a N-terminal hexahistidine tag were 
prepared in a pET22b vector. The plasmids were transformed into E. coli Nico21 (DE3) 
pLemo competent cells (New England Biolabs, Ipswich, MA). Cells were grown at 37°C in 
2xYT media with 35 g/mL chloramphenicol, 50 µg/mL ampicillin, and 0.5 mM L- 
rhamnose, while shaking at 225 rpm. At the optimal density at 600 nm (OD600) of 0.4, the 
cells were transferred to 30°C. Protein expression was induced with 0.5 mM isopropyl β-D- 
thiogalactoside (IPTG, Anatrace, Maumee, OH) at OD600 = 0.6. After 4 hours of induction, 
cells were harvested by centrifugation at 4,000 rpm for 20 min at 4C. The cell pellet was 
resuspended in 25 mM Tris-HCl pH 7.5, 1 M NaCl, 10% glycerol, 5 mM β-mercaptoethanol 
(βME) in the presence of protease inhibitors (PMSF, benzamidine, picrate) and lysed by 
passing through a microfluidizer for four times. Subsequently, the lysate was centrifugated 
at 12,000 rpm for 30 min at 4C to remove insoluble cellular components and unbroken cells. 
The supernatant was then ultracentrifuged at 45,000 rpm for 30 min at 4C to isolate 
membrane fraction. 
 
 
The membrane pellet was resuspended in 10 mM HEPES pH 7.5, 1 M NaCl, 10% glycerol, 
1% DM, 5 mM βME, and rocked for two hours at 4°C. The solubilized membrane 
components were collected as a supernatant after an ultracentrifugation at 45,000 rpm for 
30 min at 4C. The supernatant was supplemented with 10 mM imidazole and loaded onto 
pre-equilibrated 1 mL Ni-NTA agarose resin (Qiagen, Germantown, MD). The resin was 
151 
 
incubated overnight at 4°C and then was washed with 50 CV of 10 mM HEPES, pH 7.5, 
 
1 M NaCl, 10% glycerol, 0.15% DM, 5 mM βME. The protein was washed and eluted with 
increasing concentrations of EDTA (10, 30, and 200 mM), each with 20 CV, in 10 mM 
HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 0.15% DM, 5 mM βME. Fractions containing 
the protein, confirmed by a SDS-PAGE, were pooled, concentrated with a 50 kDa MWCO 
centrifugal filter (Amicon Ultra-4), and buffer exchanged into 20 mM HEPES pH 7.5, 50 
mM NaCl, 10% glycerol, 0.15% DM, 5 mM βME. The protein was further purified by 
cation-exchange chromatography (Uno S6, Bio-Rad, Hercules, CA), eluted in the range of 
270 - 650 mM NaCl, followed by size-exclusion chromatography (Superdex 200 10/300 
GL; GE Healthcare, Little Chalfont, UK), eluted in 20 mM HEPES pH 7.5, 100 mM NaCl, 
10% glycerol, 0.15% DM, 5 mM βME. The protein-containing fractions were pooled, 
concentrated with a 50 kDa MWCO centrifugal filter, flash frozen in liquid N2, and stored at 
-80°C for further assays. 
 
 
Isolation of UDP-MurNAc-L-Ala--D-Glu-m-DAP-D-Ala-D-Ala (UDP-MurNAc- 
pentapeptide) 
UDP-MurNAc-pentapeptide was isolated from Bacillus cereus (strain Frankland and 
Frankland, ATCC 14579 (Manassas, VA)) according to the protocol used in Kohlrausch et 
al., with some modifications. Briefly, B. cereus was grown in LB at 30°C to OD600 = 0.75. 
The cells were incubated for 15 min after 130 mg/L chloramphenicol was added. 
Incubation was continued for 60 min following the addition of 15 mg/L vancomycin. The 
cells were harvested by centrifugation at 4,000 rpm for 15 min at 4°C. The pellet was 
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resuspended in distilled water (0.1 g wet weight/mL) and stirred into the same volume of 
boiling water. After 15 min of boiling, suspension was allowed to cool to 4 °C and 
centrifugated at 45,000 rpm for 60 min at 4°C. The supernatant was flash frozen, stored at - 
80°C overnight, and lyophilized. Then, the lyophilized sample was dissolved in water (10 
mL/1L culture) adjusted to pH 2 by addition of 20 % H3PO4. After centrifugation (4,000 
rpm, 10 min, 4°C), the supernatant was dialyzed against 10 mM Tris-HCl pH 8.8, and 
separated via anion-exchange chromatography (Resource Q, Bio-Rad, Hercules, CA), eluted 
with a 0 - 1M NH4Ac gradient. Fractions containing UDP-MurNAc-pentapeptide in the 
range of 360 - 440 mM NH4Ac were pooled, lyophilized, and confirmed by high-resolution 
MS (Expected [MH]+= 1426.22 Da; 1427.0 Da observed). Its concentration was determined 
by spectrophotometry by using 260 = 5.8 × 104 L⋅mol-1⋅cm-1. 
 
Preparation of undecaprenyl phosphate 
 
Undecaprenyl phosphate was obtained from Larodan Fine Chemicals AB (Malmö, Sweden). 
 
 
Deoxy UMP exchange reaction and LC-MS analysis 
 
HyMraY for exchange reactions was prepared as above with slight modifications. Following 
the Ni-NTA column, pooled fractions were run on an Uno S6 column twice and with double 
volume of eluent in order to wash away all the endogenous undecaprenyl phosphate in the 
sample. After the gel-filtration column, purified HyMraY (5 ug, 0.6 uM) was incubated with 
UDP-MurNAc-pentapeptide (5 µL, 12.5 µM;) and deoxy UMP (5 µL, 25µM) in 178 µL 50 
mM Tris-HCl pH 8.0, 170 mM KCl, and 10 mM MgCl2. Either undecaprenyl phosphate (5 
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µL, 28.5 µM in 4% DM) was added to reaction or equal volume of 4% DM was added  
into three reactions that were incubated at RT for 30 min, 4 hours, and 21 hours, respectively, 
followed by heat treatment (3 min, 100°C) to stop the reactions. Reactions were extracted 
with BuOH (200 µL) and water phase was washed with EtOAc (200 µL, four times) to 
remove detergent. Then, the samples were flash frozen, lyophilized, and analyzed by LC- 
MS as described below. 
 
 
Samples were analyzed by LC-MS using a Waters UPLC/LCT Premier XE TOF mass 
spectrometer by electrospray ionization in the positive ion mode with a reversed-phase BEH 
C18 2.1x50 mm column. Mobile phases were water and acetonitrile with 0.1% formic acid. 
Chromatography was performed at a flow rate of 0.33 mL/min at 40 °C using a mobile phase 
gradient from 10% acetonitrile to 90% acetonitrile in 8 minutes. The mass spectrometer 
settings were: capillary voltage = 3kV, cone voltage = 65, source temperature = 120 °C, and 
desolvation temperature = 350 °C. 
 
 
UMP/dUMP inhibition of MraY enzymatic reaction 
 
Deoxy UMP and UMP were purchased from Sigma-Aldrich (St. Louis, MO). 5 µM, 50 µM, 
and 5 mM of UMP or dUMP was added to the reaction mixture in a final volume of 200 µL, 
which contains 20 mM HEPES pH 7.5, 100 mM NaCl, 5% glycerol, 40 mM MgCl2, 0.15% 
DM, 33 µM undecaprenyl phosphate, and 475 nM purified HyMraY. Reactions were 
initiated by the addition of 1 µM of UDP-MurNAc-pentapeptide-DNS and incubated at 37°C 
for 30 min with gentle mixing. Reactions were terminated by heat treatment (3 min, 100 °C). 
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Fluorescence was measured (excitation 340 nm, emission 380–700 nm) using a 96-
well plate reader (TECAN). 
 
 
Synthesis of UDP-MurNAc-L-Ala--D-Glu-m-DAP(N-dansyl)-D-Ala-D-Ala (UDP- 
MurNAc-pentapeptide-DNS) 
UDP-MurNAc-pentapeptide-DNS was synthesized by the reaction of UDP-MurNAc- 
pentapeptide with dansyl-chloride as described (Weppner & Neuhaus, 1977) with some 
modifications. Briefly, UDP-MurNAc-pentapeptide (14 mg, 0.012 mmol) was dissolved in 
4 mL of 1:1 (volume-to-volume) mixture of 0.25 M NaHCO3 and acetone and dansyl- 
chloride (72 mg, 0.24 mmol) was added. The solution was stirred for 12 hours in the dark. 
Acetone was evaporated, and the precipitate was removed by filtration. Filtrate was dialyzed 
against 10 mM Tris-HCl pH 8.8 and purified via anion-exchange chromatography, eluted in 
the range of 0 - 1M NH4Ac gradient. Fractions containing UDP-MurNAc-pentapeptide-
DNS were flash frozen, lyophilized, and confirmed by high-resolution MS (Expected 
[MH]+= 1426.22 Da; 1427.0 Da observed). 
 
 
Synthesis of phytol-P (C20-P) 
 
To a stirred solution of phytol (77.1 mg, 0.26 mmol) and tetra-n-butylammonium dihydrogen 
phosphate (441 mg, 1.3 mmol) in dry chloroform (1.5 ml) was added in one portion a solution 
of trichloroacetonitrile (0.153 ml, 1.53 mmol) in dry chloroform (1.5 ml). The reaction 
mixture was stirred at room temperature for two and a half hours. After evaporation of the 
solvent, the residue was extracted with upper phase of equilibrium 1-butanol/water mixture 
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4 
(15 ml) and the solution was washed with the lower phase of the same mixture (10 ml, 
three times). The 1-butanol solution was co-evaporated with heptane at room temperature to 
give crude product. The crude product was dissolved in n-propanol : water : 25 % ammonia 
mixture (1:1:0.02, 10 ml) and passed through a column of Dowex 50Wx8 (NH + form) 
equilibrated with the same solvent mixture. Removal of tetra-n-butylammonium cation 
which is essential for the following anion-exchange separation, was verified by TLC and 
ESI-MS and the Dowex 50Wx8 chromatography was repeated till complete removal was 
achieved (three times). The effluent was concentrated and n-propanol was added and 
evaporated from the residue (5ml, twice). The residue was dissolved in chloroform : 
methanol (2:1) and applied to a DEAE column (AcO- form) equilibrated with the same 
solvent mixture. Elution of the column with 030 mM ammonium acetate in methanol 
separated undesired phosphor-ester side product and yielded phytol phosphate. Undesired 
phytol-diphosphate was eluted with 200 mM ammonium acetate. Fractions containing 
desired phytol phosphate were passed over Sephadex LH-20 equilibrated with methanol. 
Product was isolated and analyzed by ESI-MS and 1H and 32P NMR. 
 
Site-directed mutagenesis of HyMraY 
 
All the site-directed mutations, including D117A/N/E, D118A/N/E, D265A/N/E, D193N/E, 
D196N/E, H324A, H325A, H326A, K320M were prepared in a mixture solution containing 
Phusion® High-Fidelity PCR Master Mix with HF Buffer from New England Biolabs Inc. 
(Ipswich, MA), the DNA template of the wild-type HyMraY and primers with or without 5% 
DMSO. The mixtures were initially heated up to 98°C for 30 sec, entered a 35-cycle of 
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denaturation at 98°C for 10 sec, annealing to primers either at 55 or 58°C for 20 sec, 
amplification at 74°C for 3 min, and extra 10 min at 74°C. The size of the mutant DNAs was 
checked on a 1% agarose gel and then they were treated with DpnI at 37°C for 3 hrs. 
Subsequently, the mutations were confirmed by DNA sequencing analysis. 
 
 
Stopped and continuous fluorescent activity assay of HyMraY 
 
The activity of the wild-type and mutant MraY was determined using either stopped or 
continuous fluorescent assay as described by Stachyra et al. (Stachyra, Dini, Ferrari, 
Heijenoort, et al., 2004). Reaction mixtures were prepared in a final volume of 200 µL, which 
contain 20 mM HEPES pH 7.5, 100 mM NaCl, 5% glycerol, 40 mM MgCl2, 0.15% DM, 33 
µM undecaprenyl phosphate, and 475 nM purified HyMraY. Reactions were initiated by the 
addition of 1 µM of UDP-MurNAc-pentapeptide-DNS and incubated at 37°C for 30 min 
with gentle mixing. Reactions were terminated by heat treatment (3 min, 100 °C). 
Fluorescence was measured (excitation 340 nm, emission 380–700 nm) using a 96-well 
plate reader (TECAN) for total reaction or water and butanol extracts separately following 
the separation of lipid-linked product soluble in butanol layer from unreacted UDP-
MurNAc- pentapeptide-DNS in water layer. 
 
 
Continuous assay was used to determine kinetic parameters of reaction. Reaction mixtures 
were prepared similarly as above with some modifications. While each concentration of C55- 
P (7.5, 20, 50 µM) was kept constant, concentrations of UDP-MurNAc-pentapeptide-DNS 
varied in the range between 1.27 and 13.15 µM. Each reaction that contains 500 nM HyMraY 
was initiated by injecting MgCl2 to final concentration of 40 mM in a TECAN plate reader. 
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For the first eight minutes of reaction, fluorescence was measured (excitation 340 nm, 
emission 530 nm) in every one- or two-second intervals at about 27 °C. Magellan software 
was used. 
 
 
Reconstitution of HyMraY into amphipathic polymers (amphipols) 
 
After the wild-type and mutant HyMraY were purified in the buffer containing 0.15 % DM, 
they were reconstituted in Amphipol A8-35 (Anatrace) via incubation in 1 : 5 (w/w) (protein 
: amphipols) and rocked for four hours at 4°C. Detergent was removed by addition of Bio- 
Beads SM-2 (Bio-Rad) at 20 g wet beads per 1g detergent and rocked overnight at 4°C 
followed by filtration. To ensue complete detergent removal, this sample was diluted with 
buffer to below the CMC and filtered in a 30 kDa MWCO centrifugal filter (Amicon Ultra- 
15). The retained portion was subsequently filtered via size-exclusion chromatography 
(Superdex 200 10/300 GL; GE Healthcare, Little Chalfont, UK), eluted in 20 mM HEPES 
pH 7.5, 100 mM NaCl, 10 % glycerol, 5 mM βME. The reconstituted HyMraY in Apols was 
tested for activity and shows no change as compared to initial detergent conditions (Data not 
shown). 
 
 
Quantification of UDP-MurNAc-pentapeptide-DNS binding to HyMraY using fluorescence 
anisotropy 
All fluorescence anisotropy measurements were performed using the wild-type and mutant 
HyMraY in Apols. The protein was titrated into a buffer containing 1 µM UDP-MurNAc- 
pentapeptide-DNS at 25°C. (20 mM HEPES pH 7.5, 100 mM NaCl, 40 mM MgCl2, 10% 
glycerol, 0.15% DM or 10 mM HEPES pH 7.5, 10% glycerol, 150 mM NaCl, 0.03% DDM). 
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Fluorescence anisotropy was measured at 550 nm (Fluorolog-322, 340 nm excitation) at 
steady state (20 min) and recorded as the mean of four readings. Control measurements were 
done in Mg2+-free conditions. Disassociation constants were fit to the data assuming a single 
binding site. 
159 
 
ACKNOWLEDGEMENTS 
 
We are grateful to the Caltech CCE Multiuser Mass Spectrometry Laboratory for sample 
analysis and to the National Science Foundation (CRIF 0541745) for enabling the purchase 
of the Waters LC-MS system used in this work. 
160 
 
C h a p t e r 6 
 
 
Concluding remarks 
 
This thesis has focused on discussing three bacterial proteins that can serve as potential 
targets for designing new antibiotics. All three proteins catalyze enzymatic reactions 
involving one or more monosaccharide(s) and contribute their products to the assembly of 
more complicated glycoconjugates that play essential roles in the cell. 
 
 
The protein, Gne described in Chapter 2 produces a GalNAc residue to synthesize three 
major glycoconjugates that decorate the surface of the human pathogen, Campylobacter 
jejuni. Since involvement of these carbohydrate structures in causing human gastroenteritis 
had been suggested, inhibiting CjGne is one strategy to attenuate or abolish pathogenesis of 
C. jejuni. Structural details at a near-atomic level and biochemical data of CjGne discussed 
here provide information on unique features of this protein compared to its related enzymes, 
which will be useful for designing an inhibitor compound. 
 
 
Two other proteins, MraY and MurG, were discussed in Chapter 3 with the introduction of 
the peptidoglycan layer that is the major constituent of the bacterial cell wall, protecting the 
cell from internal osmotic pressure and maintaining the cell shape. MraY and MurG together 
produce a building block, Lipid II or a lipid-linked disaccharide pentapeptide, for the 
peptidoglycan. Chapter 3 focused on the structural investigation of MraY from thermophiles, 
Hydrogenivirga sp. and Mycobacterium thermoresistibile, and MurG from 
161 
 
Hydrogenivirga sp. I have taken advantage of thermal stability of these proteins for 
purification and crystallization. However, the long-term goal is to study MraY and MurG 
from Mycobacterium tuberculosis, which is the causative agent of human tuberculosis. 
Chapter 5 discussed the mechanistic perspective of HyMraY based on the kinetic and 
biochemical data, which will be further informative once a substrate(s)-bound MraY 
structure is determined. 
 
 
Lastly, Chapter 4 discussed the structural studies of MraY from Escherichia coli in complex 
with its novel type of inhibitor, lysis protein E from the phage ΦX174. Structure 
determination of this EcMraY-E complex will enable us to visualize molecular interaction 
between EcMraY and protein E. I made some improvement in resolution of X-ray datasets 
compared to what we previously had, but a near-atomic resolution has to be achieved to 
correctly build a model into electron density. Once this is accomplished, protein E can be 
further modified to become more potent and eventually used to treat patients with urinary 
tract infection caused by uropathogenic strains of E. coli. 
 
 
In conclusion, I hope this thesis conveys the importance of fully understanding of a protein 
target for designing therapeutics for infectious diseases. Not only in vitro structural and 
biochemical analysis, but also in vivo functional analysis of a target protein are required to 
develop effective antibacterial agents. Interdisciplinary collaboration across fields such as 
structural biology, biochemistry, synthetic chemistry, microbiology will accelerate this 
process and we will be one step closer to combating antibiotic resistance. 
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